Ekso Bionics (EKSO) 10-K 15 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 01, 2017	Jun. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Registrant Name	EKSO BIONICS HOLDINGS, INC.
Entity Central Index Key	1,549,084
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 58,706,755
Trading Symbol	EKSO
Entity Common Stock, Shares Outstanding		21,902,212

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash	$ 16,846	$ 19,552
Accounts receivable, net of allowances of $107 and $93, respectively	1,780	2,069
Inventories, net	1,556	1,056
Prepaid expenses and other current assets	502	436
Deferred cost of revenue, current	0	2,088
Total current assets	20,684	25,201
Property and equipment, net	2,435	2,625
Deferred cost of revenue	0	2,502
Intangible assets, net	1,026	1,584
Goodwill	189	189
Other assets	91	97
Total assets	24,425	32,198
Current liabilities:
Accounts payable	1,879	2,694
Accrued liabilities	3,556	1,885
Deferred revenues, current	825	3,960
Capital lease obligation, current	54	80
Total current liabilities	6,314	8,619
Deferred revenues	805	4,613
Note payable, net	6,789	0
Warrant liability	3,546	9,195
Contingent consideration liability	217	768
Contingent success fee liability	116	0
Other non-current liabilities	107	195
Total liabilities	17,894	23,390
Commitments and contingencies (Note 16)
Stockholders' equity:
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; none and 13 issued and outstanding at December 31, 2016 and 2015, respectively	0	0
Common stock, $0.001 par value; 71,429 shares authorized; 21,894 and 15,027, shares issued and outstanding at December 31, 2016 and 2015, respectively	22	15
Additional paid-in capital	121,291	100,185
Accumulated other comprehensive income (loss)	79	(1)
Accumulated deficit	(114,861)	(91,391)
Total stockholders' equity	6,531	8,808
Total liabilities and stockholders' equity	$ 24,425	$ 32,198

Consolidated Balance Sheets _Pa

Consolidated Balance Sheets [Parenthetical] - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accounts receivable, allowance	$ 107	$ 93
Convertible Preferred stock, par value per share	$ 0.001	$ 0.001
Convertible Preferred stock, shares authorized	10,000	10,000
Convertible Preferred stock, shares issued	0	13
Convertible Preferred stock, shares outstanding	0	13
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	71,429	71,429
Common Stock, Shares, Issued	21,894	15,027
Common Stock, Shares, Outstanding	21,894	15,027

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016		Dec. 31, 2015	Dec. 31, 2014
Revenue:
Device and related	$ 13,334		$ 4,252	$ 2,924
Engineering services	887		4,409	2,403
Total revenue	14,221		8,661	5,327
Cost of revenue:
Device and related	10,715		3,926	2,048
Engineering services	559		3,556	1,720
Total cost of revenue	11,274		7,482	3,768
Gross profit	2,947		1,179	1,559
Operating expenses:
Sales and marketing	10,997		9,258	7,085
Research and development	8,879		6,480	3,868
General and administrative	10,853		7,002	7,400
Change in fair value, contingent consideration	(196)		0	0
Total operating expenses	30,533		22,740	18,353
Loss from operations	(27,586)		(21,561)	(16,794)
Other income (expense), net:
Interest expense	(16)		(13)	(435)
Warrant issuance expense	0		(487)	0
Gain (loss) on warrant liability	4,286		2,505	(16,485)
Interest income	12		11	6
Other expense, net	(166)		(45)	(61)
Total other income (expense), net	4,116		1,971	(16,975)
Net loss	(23,470)		(19,590)	(33,769)
Less: Preferred deemed dividend	10,345		4,655	0
Net loss applicable to common shareholders	(33,815)	[1]	(24,245)	(33,769)
Foreign currency translation adjustments	80		(1)	0
Comprehensive loss applicable to common shareholders	$ (33,735)		$ (24,246)	$ (33,769)
Basic net loss per share applicable to common shareholders (in dollars per share)	$ (1.87)	[1]	$ (1.66)	$ (3.02)
Diluted net loss per share applicable to common shareholders (in dollars per share)	$ (2.05)	[1]	$ (1.83)	$ (3.02)
Weighted average number of shares outstanding, basic (in shares)	18,126	[1]	14,606	11,181
Weighted average number of shares outstanding, diluted (in shares)	18,622	[1]	14,609	11,181
[1]	Recognition of previously deferred revenue and cost of goods in the year ended December 31, 2016 reduced net loss applicable to common stockholders by $2,358, or $0.13 per share (see Note 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates – Medical Device Revenue and Cost of Revenue Recognition).

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) shares in Thousands, $ in Thousands	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2013	$ (36,373)	$ 27,324	$ 3	$ 1,656	$ 0	$ (38,032)
Balance (in shares) at Dec. 31, 2013		25,924	3,016
Issuance of common stock upon exercise of stock options	2		$ 0	2	0	0
Issuance of common stock upon exercise of stock options (in shares)			13
Fair value of warrant liability transferred to equity upon net exercise	282		$ 0	282	0	0
Fair value of warrant liability transferred to equity upon net exercise (in shares)		767
Conversion of preferred stock	27,324	$ (27,324)	$ 4	27,320	0	0
Conversion of preferred stock (in shares)		(26,691)	3,813
Balance at Jan. 14, 2014	(8,765)	$ 0	$ 7	29,260	0	(38,032)
Balance (in shares) at Jan. 14, 2014		0	6,842
Balance at Dec. 31, 2013	(36,373)	$ 27,324	$ 3	1,656	0	(38,032)
Balance (in shares) at Dec. 31, 2013		25,924	3,016
Net loss	(33,769)
Foreign currency translation adjustments	0
Balance at Dec. 31, 2014	22,800	$ 0	$ 15	94,586	0	(71,801)
Balance (in shares) at Dec. 31, 2014		0	14,517
Balance at Jan. 14, 2014	(8,765)	$ 0	$ 7	29,260	0	(38,032)
Balance (in shares) at Jan. 14, 2014		0	6,842
PPO shares issued for cash	25,300	$ 0	$ 4	25,296	0	0
PPO shares issued for cash (in shares)			3,614
PPO shares issued upon conversion of 2013 Bridge Notes	5,082	0	$ 1	5,081	0	0
PPO shares issued upon conversion of 2013 Bridge Notes (in shares)			714
Shares issued to consultant in PPO	0		$ 0	0	0	0
Shares issued to consultant in PPO (in shares)			36
Fair value of warrant obligation transferred to equity	96	0	$ 0	96	0	0
Unamortized debt discounts transferred to equity	(947)	0	0	(947)	0	0
Offering costs of PPO shares	(3,339)	0	0	(3,339)	0	0
Issuance of common stock warrants at fair value	(10,614)	0	0	(10,614)	0	0
Balance at Jan. 16, 2014	6,813	$ 0	$ 12	44,833	0	(38,032)
Balance (in shares) at Jan. 16, 2014		0	11,206
Issuance of common stock upon exercise of warrants	21,412	$ 0	$ 3	21,409	0	0
Issuance of common stock upon exercise of warrants (in shares)			3,269
Fair value of warrant anti-dilution feature transferred to equity	27,099	0	$ 0	27,099	0	0
Issuance of common stock upon exercise of stock options	102	0	$ 0	102	0	0
Issuance of common stock upon exercise of stock options (in shares)			42
Stock-based compensation expense	1,143	0	$ 0	1,143	0	0
Net loss	(33,769)	0	0	0	0	(33,769)
Balance at Dec. 31, 2014	22,800	$ 0	$ 15	94,586	0	(71,801)
Balance (in shares) at Dec. 31, 2014		0	14,517
Issuance of common stock/preferred stock	14,218	$ 0	$ 0	14,218	0	0
Issuance of common stock/preferred stock (in shares)		15	0
Allocation of proceeds from Series A preferred stock to warrant liability	(11,700)	$ 0	$ 0	(11,700)	0	0
Beneficial conversion feature on Series A preferred stock	3,300	0	0	3,300	0	0
Conversion of Series A convertible preferred stock to common stock and accretion of Series A convertible preferred stock discount	1,356	$ 0	$ 0	1,356	0	0
Conversion of Series A convertible preferred stock to common stock and accretion of Series A convertible preferred stock discount (in shares)		(2)	246
Deemed dividend on Series A convertible preferred stock	(4,655)	$ 0	$ 0	(4,655)	0	0
Issuance of common stock for assets acquired from Equipois	1,071	0	$ 0	1,071	0	0
Issuance of common stock for assets acquired from Equipois (in shares)			112
Issuance of common stock upon exercise of warrants	53	0	$ 0	53	0	0
Issuance of common stock upon exercise of warrants (in shares)			7
Issuance of common stock upon exercise of stock options	225	0	$ 0	225	0	0
Issuance of common stock upon exercise of stock options (in shares)			145
Stock-based compensation expense	1,731	0	$ 0	1,731	0	0
Net loss	(19,590)	0	0	0	0	(19,590)
Foreign currency translation adjustments	(1)	0	0	0	(1)	0
Balance at Dec. 31, 2015	8,808	$ 0	$ 15	100,185	(1)	(91,391)
Balance (in shares) at Dec. 31, 2015		13	15,027
Shares issued as a result of rounding due to reverse-stock split	0	$ 0	$ 0	0	0	0
Shares issued as a result of rounding due to reverse-stock split (in share)			8
Issuance of common stock/preferred stock	14,694	$ 0	$ 4	14,690	0	0
Issuance of common stock/preferred stock (in shares)		0	4,017
Conversion of Series A convertible preferred stock to common stock and accretion of Series A convertible preferred stock discount	10,345	$ 0	$ 3	10,342	0	0
Conversion of Series A convertible preferred stock to common stock and accretion of Series A convertible preferred stock discount (in shares)		(13)	2,310
Deemed dividend on Series A convertible preferred stock	(10,345)	$ 0	$ 0	(10,345)	0	0
Issuance of common stock upon exercise of warrants	3,188	0	$ 0	3,188	0	0
Issuance of common stock upon exercise of warrants (in shares)			488
Issuance of common stock upon exercise of stock options	110	0	$ 0	110	0	0
Issuance of common stock upon exercise of stock options (in shares)			44
Stock-based compensation expense	3,121	0	$ 0	3,121	0	0
Net loss	(23,470)	0	0	0	0	(23,470)
Foreign currency translation adjustments	80	0	0	0	80	0
Balance at Dec. 31, 2016	$ 6,531	$ 0	$ 22	$ 121,291	$ 79	$ (114,861)
Balance (in shares) at Dec. 31, 2016		0	21,894

Consolidated Statements of Sto6

Consolidated Statements of Stockholders' Equity (Deficit) [Parenthetical] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Payment of Financing and Stock Issuance Costs	$ 1,373	$ 779

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating activities
Net loss	$ (23,470)	$ (19,590)	$ (33,769)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	1,855	933	745
Inventory allowance expense	30	34	(36)
Amortization of deferred rent	(36)	(37)	(36)
Amortization of debt discounts	0	0	208
Finance cost attributable to issuance of warrants	0	487	0
Interest expense accrued to convertible notes	0	0	20
Interest income added to note receivable from stockholder	0	0	3
Change in fair value of contingent consideration liability	(196)	0	0
Stock-based compensation expense	3,121	1,731	1,143
Change in fair value of warrant liability	(4,286)	(2,505)	16,485
Unrealized loss on foreign currency transactions	135	0	0
Changes in operating assets and liabilities
Accounts receivable	154	(520)	(1,000)
Inventories	(541)	(200)	354
Prepaid expense and other assets current and noncurrent	(60)	(91)	(36)
Deferred cost of revenue	4,590	(1,022)	(1,995)
Accounts payable	(818)	1,738	(716)
Accrued liabilities	1,468	(493)	944
Deferred revenues	(6,943)	1,266	2,679
Net cash used in operating activities	(24,997)	(18,269)	(15,007)
Investing activities
Acquisition of property and equipment, net	(1,096)	(1,492)	(1,487)
Net cash used in investing activities	(1,096)	(1,492)	(1,487)
Financing activities
Principal payments on notes payable	(79)	(60)	(2,596)
Fees paid related to 2015 issuance of convertible preferred stock	(173)	0	0
Proceeds from issuance of common stock, net	14,694	0	21,961
Proceeds from issuance of convertible preferred stock and warrants, net	0	13,906	0
Proceeds from exercise of stock options	110	225	102
Proceeds from exercise of common stock warrants	1,825	53	21,412
Proceeds from issuance of long-term debt, net of financing costs	6,930	0	0
Net cash provided by financing activities	23,307	14,124	40,879
Effect of exchange rate changes on cash	80	(1)	0
Net (decrease) increase in cash	(2,706)	(5,638)	24,385
Cash at beginning of the period	19,552	25,190	805
Cash at end of the period	16,846	19,552	25,190
Supplemental disclosure of cash flow activities
Cash paid for interest	16	12	138
Cash paid for income taxes	33	5	38
Supplemental disclosure of non-cash activities
Acquisition of property and equipment with capital lease	0	166	0
Transfer of property and equipment to inventory	11	0	0
Contingent success fee liability for term loan	116	0	0
Preferred deemed dividend to common shareholders in connection with anti-dilution feature associated with issuance of Series A preferred warrants	10,345	4,655	0
Issuance of Series A preferred stock warrants	0	11,700	0
Acquisition of Equipois assets with common stock and contingent consideration liability	0	1,839	0
Conversion of bridge loan to common stock	0	0	5,082
Conversion of convertible preferred stock to common stock	3	0	27,324
Conversion of preferred stock warrants to common stock warrants	0	0	282
Reclassification of warrant liability to equity upon exercise of warrants	$ 1,363	$ 0	$ 27,099

Organization

Organization	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Description of Business On January 15, 2014, a wholly-owned subsidiary of Ekso Bionics Holdings, Inc. named Ekso Acquisition Corp. merged with and into Ekso Bionics, Inc. (the “Merger”). Ekso Bionics, Inc. was the surviving corporation and became a wholly-owned subsidiary of Ekso Bionics Holdings, Inc. As a result of this transaction, Ekso Bionics Holdings, Inc. discontinued its pre-merger operations, acquired the business of Ekso Bionics, Inc. and continues the operations of Ekso Bionics, Inc. as a publicly traded company. See Note 3, 2014 Merger, Offering and Other Related Transactions. As used in these notes to the consolidated financial statements, the term “the Company” refers to Ekso Bionics Holdings, Inc. formerly known as PN Med Group, Inc., and its wholly-owned subsidiaries, including Ekso Bionics, Inc. after giving effect to the Merger; the term “Holdings” refers to the business of Ekso Bionics Holdings, Inc. prior to the Merger, and the term “Ekso Bionics” refers to Ekso Bionics, Inc. prior to the Merger. Unless otherwise indicated, all dollar and share amounts included in these notes to the consolidated The Company designs, develops, and sells exoskeletons that augment human strength, endurance and mobility. The Company’s exoskeletons have applications in health care, industrial, military, and consumer markets. Liquidity and Going Concern Largely as a result of significant research and development activities related to the development of the Company’s advanced technology and commercialization of this technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. The Company has also recognized significant non-cash losses associated with the revaluation of certain securities, which have also contributed significantly to its accumulated deficit. As of December 31, 2016, the Company had an accumulated deficit of $ 114,861 Cash on hand at December 31, 2016 was $ 16,846 19,552 24,972 18,269 As noted in Note 9, Long-Term Debt on hand roughly equivalent to three months of cash burn. As of January 31, 2017, the most recent determination of this restriction, $6,026 of cash must remain as unrestricted, with such amounts to be re-computed at each month end period. After considering cash such restriction, effective unrestricted cash as of December 31, 2016 is estimated to be $10,820. Based on current forecasted amounts, our on hand these consolidated financial statements, Based upon the Company’s current cash resources, the recent rate of using cash for operations and investment, and assuming modest increases in current revenue offset by incremental increases in expenses related to increased sales and marketing and research and development, and a potential increase in rental activity from its medical device business, the Company believes it has sufficient resources to meet its financial obligations into the third quarter of 2017. The Company will require significant additional financing. The Company is actively pursuing opportunities to obtain additional financing in the future through public or private equity and/or debt financings, corporate collaborations, or warrant solicitations. The Company’s actual capital requirements may vary significantly and will depend on many factors. For example, the Company plans to continue to increase its investments (i) in its clinical, sales and marketing initiatives to accelerate adoption of the Ekso robotic exoskeleton in the rehabilitation market, (ii) in its research, development and commercialization activities with respect to an Ekso robotic exoskeleton for home use, and/or (iii) in the development and commercialization of able-bodied exoskeletons for industrial use. Consequently, the Company will require significant additional financing in the future, which the Company intends to raise through corporate collaborations, public or private equity offerings, debt financings, or warrant solicitations. Sales of additional equity securities by us could result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required in sufficient amounts, on acceptable terms or at all. In the event that the necessary additional financing is not obtained, the Company may be required to reduce its discretionary overhead costs substantially, including research and development, general and administrative, and sales and marketing expenses or otherwise curtail operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Estimates	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Estimates	2. Summary of Significant Accounting Policies and Estimates The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). All significant intercompany transactions and balances have been eliminated in consolidation. Certain reclassifications have been made to conform to the current period’s presentation. All common share and per share amounts have been adjusted to reflect the one-for-seven reverse stock split completed on May 4, 2016. See Note 13, Capitalization and Equity Structure – Reverse Stock Split The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of associated costs, valuation of acquired intangible assets and goodwill, useful lives assigned to long-lived assets, realizability of deferred tax assets, valuation of common and preferred stock warrants, the valuation of options, and contingencies. Actual results could differ from those estimates. The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income (loss) as a component of stockholders’ equity. Where the U.S. dollar is the functional currency, re-measurement adjustments are recorded in other comprehensive income (loss), net in the accompanying consolidated statements of operations and comprehensive loss. Gains and losses realized from transactions, including related party balances not considered permanent investments, that are denominated in currencies other than an entity’s functional currency are included in other expense Accumulated other comprehensive income (loss) reported on our consolidated balance sheets consists of foreign currency translation adjustments. Foreign Currency Translation Balance at December 31, 2015 $ (1) Other comprehensive loss before reclassification 80 Amounts reclassified from accumulated other comprehensive income (loss) - Net current period other comprehensive income 80 Balance at December 31, 2016 $ 79 The Company considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents. The Company’s cash is deposited in bank accounts with the Company’s primary cash management bank. The Company places its cash and cash equivalents in highly liquid instruments with, and in the custody of, financial institutions with high credit ratings. The Company did not have any cash equivalents or investments in money market funds as of December 31, 2016 and 2015. Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains our cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable. Accounts receivable are derived from the sale of products shipped and services performed for customers located in the U.S. and throughout the world. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for credit losses, as needed. The Company has not experienced material losses related to accounts receivable during the years ended December 31, 2016 and December 31, 2015. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling foreign contracts. At December 31, 2016, the Company had three customers with accounts receivable balances totaling 10 18 16 11 10 22 11 For the year ended December 31, 2016, the Company had no customers with billed revenue of 10 33 12 Inventories are recorded at the lower of cost or market value. Cost is principally determined using the average cost method. Parts from vendors are received and recorded as raw material. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress (“WIP”). Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge to the consolidated statements of operations and comprehensive loss Property and equipment are stated at cost less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally ranging from three to thirteen years. Leasehold improvements are amortized over the shorter of the estimated useful life of ten years or the related term of the lease. The costs of repairs and maintenance are expensed when incurred, while expenditures for refurbishments and improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized. When assets are retired or sold, the asset cost and related accumulated depreciation or amortization are removed from the accompanying consolidated balance sheets, with any gain or loss reflected in the accompanying consolidated statements of operations and comprehensive loss. The Company has evaluated its lease obligations and does not have any material asset retirement obligations. The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that their carrying value may not be recoverable from the estimated future cash flows expected to result from their use or eventual disposition. If estimates of future undiscounted net cash flows are insufficient to recover the carrying value of the assets, the Company will record an impairment loss in the amount by which the carrying value of the assets exceeds the fair value. If the assets are determined to be recoverable, but the useful lives are shorter than originally estimated, the Company will depreciate or amortize the net book value of the assets over the newly determined remaining useful lives. None of the Company’s property and equipment or intangible assets were impaired as of December 31, 2016 and 2015. Accordingly, no impairment loss has been recognized in the years ended December 31, 2016, 2015, and 2014. The Company records goodwill when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. We perform an annual impairment assessment in the fourth quarter of each year, or more frequently if indicators of potential impairment exist, which includes evaluating qualitative and quantitative factors to assess the likelihood of an impairment of goodwill. We perform impairment tests using a fair value approach when necessary. None of the Company’s goodwill was impaired as of December 31, 2016 and 2015. Accordingly, no impairment loss has been recognized in the years ended December 31, 2016, 2015, and 2014. For further discussion of goodwill, see Note 4 Equipois Acquisition We account for hybrid contracts that feature conversion options in accordance with generally accepted accounting principles in the United States. Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging Activities Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument. We account for convertible instruments when we have determined that the embedded conversion options should not be bifurcated from their host instruments, in accordance with ASC 470-20, Debt with Conversion and Other Options We also follow ASC 480-10, Distinguishing Liabilities from Equity We generally account for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that we may need to settle the warrants in cash. For warrants where there is a possibility that we may have to settle the warrants in cash, we estimate the fair value of the issued warrants as a liability at each reporting date and record changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. model Option Pricing model The Company’s common stock price represents a significant input that affects the valuation of the warrants We account for business combinations under the acquisition method of accounting in accordance with ASC 805, Business Combinations Contingent consideration, if any, is recorded at the acquisition date based upon the estimated fair value of the contingent payments. The fair value of the contingent consideration is re-measured each reporting period with any adjustments in fair value being recognized in loss from operations. The purchase price in excess of the fair value of the tangible and identified intangible assets acquired less liabilities assumed is recognized as goodwill. We assess our ability to continue as a going concern at every interim and annual period in accordance with ASC 205-40. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The ability to meet our obligations as they come due and the attainment of sustainable profitability and positive cash flow from operations is dependent on certain future events. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. We evaluate whether it is probable that our plans to mitigate those conditions will alleviate that substantial doubt at every interim and annual period and disclose the conditions giving rise to substantial doubt and the results of our evaluation. Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis over the life of the lease. The Company recognizes revenue when the four basic criteria of revenue recognition are met: · Persuasive evidence of an arrangement exists. Customer contracts and purchase orders are generally used to determine the existence of an arrangement. · The transfer of technology or products has been completed or services have been rendered. Evidence of shipment or customer acceptance, when applicable, is used to verify delivery. · The sales price is fixed or determinable. The Company assesses whether the cost is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. · Collectability is reasonably assured. The Company assesses collectability based primarily on the creditworthiness of the customer as determined by credit checks and analysis as well as the customer’s payment history. When collaboration, other research arrangements, and product sales include multiple-element revenue arrangements, we account for these transactions by determining the elements, or deliverables, included in the arrangement and determining which deliverables are separable for accounting purposes. We consider delivered items to be separable if the delivered item(s) have stand-alone value to the customer and delivery or performance of the undelivered item is considered probable and substantially in control of the vendor. Medical Device Revenue and Cost of Revenue Recognition The Company builds medical device robotic exoskeletons for sale and capitalizes into inventory materials, direct and indirect labor and overhead in connection with manufacture and assembly of these units. When the Company brought its first version medical device to market in 2012, the Company could not be certain as to the costs it would incur to support, maintain, service, and upgrade these early stage devices. Primarily for this reason, prior to January 1, 2016, the sale of a device, associated software, initial training, and extended support and maintenance were deemed as a single unit of accounting due to the uncertainty of the Company’s follow-up maintenance and upgrade expenses, which were forecast to extend over three years. Accordingly, the revenue from the sales of the device and associated cost of revenue were deferred at the time of shipment. Upon completion of training, the amount of the arrangements were recognized as revenue and cost of revenue over a three year period on a straight line basis, while all service expenses, whether or not covered by the Company’s original warranty, extended warranty contracts, or neither, were recognized as incurred. Effective January 1, 2016, the Company determined it had established (i) separate individual pricing for training, extended warranty coverage, and out-of-contract service or repairs, (ii) sufficient historical evidence of customer buying patterns for extended warranty and maintenance coverage, and (iii) a basis for estimating and recording warranty and service costs to allow the Company to separate its multiple element arrangements into two distinct units of accounting: (1) the device, associated software, original manufacturer warranty and training if required, and (2) extended support and maintenance. As a result, in the first quarter of 2016, the Company began to recognize revenue related to its sales transactions on a multiple element approach in which revenue is recognized upon the delivery of the separate elements to the customer. Revenue relating to the undelivered elements is deferred using the relative selling price method, which allocates revenue to each element using the estimated selling prices for the deliverables when vendor-specific objective evidence or third-party evidence is not available. For sales on or after January 1, 2016, revenue and associated cost of revenue of medical devices is recognized when delivered, or training has been completed, if required. Revenue for extended maintenance and support agreements is recognized on a straight line basis over the contractual term of the agreement, which typically ranges from one to four years. As a result of this change, the Company recognized medical device revenue previously deferred at December 31, 2015 of $ 6,517 4,159 2,358 , or $0.13 per share, 212 911 The Company builds industrial exoskeletons for sale and capitalizes into inventory materials, direct and indirect labor, and overhead in connection with the manufacture and assembly of these units. No right of return exists on sales of industrial exoskeletons. We assess collectability at the time of the sale and if collectability is not reasonably assured, the sale is deferred and not recognized until collectability is probable or payment is received. Typically, where product is produced and sold in the same country, title and risk of ownership transfer when the product is shipped. Products that are exported from a country for sale typically pass title and risk of ownership at the border of the destination country. Because our industrial products are produced in the U.S., title and risk of ownership generally transfer when the product is shipped, if shipped to a customer in the U.S. If we sell products to customers outside the U.S., title and risk of ownership is generally transferred at the border of the destination country. Engineering Services Revenue and Cost of Revenue Collaborative arrangements typically consist of cost reimbursements for specific engineering and development spending, and future product royalty payments. Cost reimbursements for engineering and development spending are recognized as the related project labor hours are incurred in relation to all labor hours and when collectability is reasonably assured. Amounts received in advance are recorded as deferred revenue until the technology is transferred, services are rendered, or milestones are reached. Product royalty payments are recorded when earned under the arrangement. Government grants, which support the Company’s research efforts in specific projects, generally provide for reimbursement of approved costs as defined in the notices of grant awards. Grant revenue is recognized as the associated project labor hours are incurred in relation to total labor hours. There are some grants, such as the National Science Foundation grants, of which the Company draws upon and spends based on budgets preapproved by the grantor. The cost of engineering services revenue includes payroll and benefits, subcontractor expenses and materials. All costs related to engineering services are expensed as incurred and reported as cost of revenue. In connection with the Company’s medical device sales and research services, the Company often receives cash payments before its earnings process is complete. In these instances, the Company records the payments as customer deposits until a device is shipped to the customer, or as customer advances in the case of research services until the earnings process is achieved. In both cases, the cash received is recorded as a component of deferred revenue. December 31, 2016 2015 Customer deposits and advances $ 47 $ 48 Deferred medical device revenues - 7,388 Deferred rental income 60 71 Deferred extended maintenance and support 1,523 1,066 Total deferred revenues 1,630 8,573 Less current portion (825) (3,960) Deferred revenues, non-current $ 805 $ 4,613 Deferred medical device unit costs $ - $ 4,590 Less current portion - (2,088) Deferred cost of revenue, non-current $ - $ 2,502 Research and development costs consist of costs incurred for internal research and development activities. These costs primarily include salaries and other personnel-related expenses, contractor fees, facility costs, supplies, and depreciation of equipment associated with the design and development of new products prior to the establishment of their technological feasibility. Such costs are expensed as incurred. Advertising costs are recorded in sales and marketing expense as incurred. Advertising expense was $ 104 25 1 The Company accounts for income taxes using the asset and liability method. Under this method, income tax expense or benefit is recognized for the amount of taxes payable or refundable for the current year and for deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company's consolidated financial statements or tax returns. The Company accounts for any income tax contingencies in accordance with accounting guidance for income taxes. The measurement of current and deferred tax assets and liabilities is based on provisions of currently enacted tax laws. The effects of any future changes in tax laws or rates have not been considered. For the preparation of the Company's consolidated financial statements included herein, the Company estimates its income taxes and tax contingencies in each of the tax jurisdictions in which it operates prior to the completion and filing of its tax returns. This process involves estimating actual current tax expense together with assessing temporary differences resulting from differing treatment of items, such as deferred revenue, for tax and accounting purposes. These differences result in net deferred tax assets and liabilities. The Company must then assess the likelihood that the deferred tax assets will be realizable, and to the extent they believe that realizability is not likely, the Company must establish a valuation allowance. In assessing the need for any additional valuation allowance, the Company considers all the evidence available to it, both positive and negative, including historical levels of income, legislative developments, expectations and risks associated with estimates of future taxable income, and ongoing prudent and feasible tax planning strategies. The Company measures stock-based compensation expense for all stock-based awards made to employees and directors based on the estimated fair value of the award on the date of grant using the Black-Scholes option pricing model and recognizes the fair value on a straight-line basis over the requisite service periods of the awards. Stock-based awards made to non-employees are measured and recognized based on the estimated fair value on the vesting date and are re-measured at each reporting period. The Company’s determination of the fair value of stock-based awards on the date of grant using the Black-Scholes option pricing model is affected by the Company’s stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to the Company’s expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Because there is insufficient information available to estimate the expected term of the stock-based awards, the Company adopted the simplified method of estimating the expected term pursuant to SEC Staff Accounting Bulletin Topic 14. On this basis, the Company estimated the expected term of options granted by taking the average of the vesting term and the contractual term of the option. The Company has, from time to time, modified the terms of its stock options to employees. The Company accounts for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification. Years ended December 31, 2016 (1) 2015 2014 Numerator: Net loss applicable to common stockholders $ (33,815) $ (24,245) $ (33,769) Adjustment for gain on fair value of warrant liability (4,286) (2,505) - Adjusted net loss used for dilution calculation $ (38,101) $ (26,750) $ (33,769) Denominator Weighted-average number of shares outstanding 18,126 14,606 11,181 Effect of potential dilutive shares 496 3 - Dilutive weighted-average number of shares outstanding 18,622 14,609 11,181 Net loss per share applicable to common stockholders Basic $ (1.87) $ (1.66) $ (3.02) Diluted $ (2.05) $ (1.83) $ (3.02) (1) Recognition of previously deferred revenue and cost of goods in the year ended December 31, 2016 reduced net loss applicable to common stockholders by $2,358, or $ 0.13 Note 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates – Medical Device Revenue and Cost of Revenue Recognition Years ended December 31, 2016 2015 2014 Options to purchase common stock 2,477 1,963 1,542 Warrants for common stock 1,963 1,963 1,971 Common stock issuable upon conversion of preferred shares - 1,876 - Total common stock equivalents 4,440 5,802 3,513 In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements – Going Concern In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs 95 In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09 Compensation – Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting so as to more closely align compensation expense to services provided In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments

2014 Merger, Offering, and Othe

2014 Merger, Offering, and Other Related Transactions	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Merger, Offering and Other Related Transactions	3. 2014 Merger, Offering, and Other Related Transactions Holdings was incorporated in the State of Nevada on January 30, 2012, as a distributor of medical supplies and equipment to municipalities, hospitals, pharmacies, care centers, and clinics in Chile. At the time of the Merger, Holdings was a “shell company” as defined in Rule 12b-2 of the Exchange Act. Holdings’ fiscal year end was previously March 31, but was changed to December 31 in connection with the Merger. On January 15, 2014, Holdings and a newly formed wholly-owned subsidiary of Holdings, Ekso Acquisition Corp. (“Acquisition Sub”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Ekso Bionics. Under the Merger Agreement, Acquisition Sub merged with and into Ekso Bionics, with Ekso Bionics remaining as the surviving corporation and with the stockholders of Ekso Bionics exchanging all of their common stock, preferred stock and warrants to purchase preferred stock issued and outstanding immediately prior to the closing of the Merger into an aggregate of 6,088 89 713 1,086 754 643 111 6.8 Upon the closing of the Merger, under the terms of a split-off agreement and a general release agreement, Holdings transferred all of its pre-Merger operating assets and liabilities to a newly formed wholly-owned special-purpose subsidiary (“Split-Off Subsidiary”), and transferred all of the outstanding shares of capital stock of Split-Off Subsidiary to two individuals who were the pre-Merger majority stockholders of Holdings and Holdings’ former officers and sole director (the “Split-Off”), in consideration of and in exchange for (a) the surrender and cancellation of an aggregate of all shares of Holdings’ common stock held by such individuals (which were cancelled and resumed the status of authorized but unissued shares of the Company’s common stock) and (b) certain representations, covenants and indemnities. Accounting for Reverse Merger Ekso Bionics, as the accounting acquirer, recorded the Merger as the issuance of stock for the net monetary assets of Holdings accompanied by a recapitalization. This accounting was identical to that resulting from a reverse merger, except that no goodwill or intangible assets were recorded. The historical financial statements of Holdings before the Merger have been replaced with the historical financial statements of Ekso Bionics before the Merger in filings with the SEC subsequent to the Merger, including this filing. The Merger was intended to be treated as a tax-free exchange under Section 368(a) of the Internal Revenue Code of 1986, as amended. Retroactive Conversion of all Share and Per Share Amounts In accordance with reverse merger accounting guidance, amounts for Ekso Bionics’ historical (pre-merger) common stock, preferred stock and warrants and options to purchase common stock including share and per share amounts have been retroactively adjusted using their respective exchange ratios in these financial statements, except for the pre-Merger amounts shown in the consolidated statement of stockholders’ equity (deficit) or unless otherwise disclosed. The conversion ratios were 1.5238 1.6290 1.9548 1.9548 Repayment of 2013 Bridge Note In November 2013, in anticipation of the Merger and related private placement offering, Ekso Bionics completed a private placement to accredited investors of $ 5,000 83 714 357 7.00 three years Private Placement Offering Concurrently with the closing of the Merger and in contemplation of the Merger, the Company held a closing of a private placement offering (the “PPO”) in which it sold 2,940 7.00 14.00 714 1,389 4,329 25,300 5,083 2,553 3,338 Investors in the Units had weighted average anti-dilution protection with respect to the shares of common stock included in the Units if within 24 months after the final closing of the PPO the Company issued additional shares of common stock or common stock equivalents (subject to customary exceptions, including but not limited to issuances of awards under the Company’s 2014 Equity Incentive Plan) for consideration per share less than $ 7.00 In connection with the conversion of the 2013 Bridge Notes and the PPO, the placement agent for the PPO and its sub-agents were paid an aggregate commission of $ 3,030 71 7.00 five years 357 five years 7.00 Offer to Amend and Exercise In November 2014, the Company consummated an offer to amend and exercise (the “Offer to Amend and Exercise”) its PPO Warrants at a temporarily reduced exercise price. Pursuant to the Offer to Amend and Exercise, an aggregate of 3,251 14.00 7.00 In connection with the Offer to Amend and Exercise, the holders of a majority of the then outstanding PPO Warrants, Bridge Warrants, PPO Agent Warrants and Bridge Agent Warrants approved an amendment to remove the price-based anti-dilution provisions in those warrants (see Note 13, Capitalization and Equity Structure – 2014 PPO and Merger Warrants 2014 Equity Incentive Plan Before the Merger, the Board of Directors adopted, and the stockholders approved, the 2014 Equity Incentive Plan, which provided for the issuance of incentive awards constituting up to 2,058 1,086 329 Subsequent to the Merger, on June 10, 2015, the Board submitted to the stockholders and the stockholders approved an amendment of the 2014 Plan to increase the maximum number of shares of common stock that may be issued under the Amended and Restated 2014 Equity Incentive Plan (the “2014 Plan”) by 1,656 3,714

Equipois Acquisition

Equipois Acquisition	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Equipois Acquisition	On December 1, 2015, the Company acquired substantially all of the assets of Equipois, LLC 1.1 The Company accounted for the acquisition as a business combination by applying the acquisition method, and accordingly, the purchase price of $ 1,839 189 The acquired assets consist of mechanical balance and support arms technologies, including the rights to the zeroG® and X-Ar® products. The acquired assets were integral to the Equipois business and include patents, trademarks and other intellectual property rights as well as certain tools and product designs and specifications. The Company also assumed the rights and obligations of Equipois under certain intellectual property license agreements. The Company did not assume any other obligations of Equipois. Amount Stock consideration (112 shares) $ 1,071 Estimated contingent consideration 768 Total purchase price $ 1,839 The fair value of the 112 In connection with the acquisition, the parties entered into a supply agreement pursuant to which Equipois supplied products to the Company during a post-closing transition period expiring December 31, 2016 (the “Supply Agreement”), and a reseller agreement pursuant to which Equipois may purchase and resell the products to certain current Equipois customers for a three-year term (the “Reseller Agreement”). Under the Supply Agreement, the Company was obligated to make a minimum purchase of $ 157 521 The fair value of the contingent consideration resulting from the Supply Agreement and Reseller Agreement was recorded at the time of acquisition. The Supply Agreement required the Company to pay $ 500 125 375 The Asset Purchase Agreement also provides for the election of a buyout payment by either the Company or Equipois which is payable in shares of the Company’s common stock. Upon the election of the buyout payment by either party, the Reseller Agreement is terminated and the buyout payment will be considered in lieu of any further annual or final earn-out payments. The buyout payment ranges from total consideration of $ 1,750 3,000 November 30, 2017 The contingent consideration is valued using the Probability Weighted Value Analysis which considered performance based contingent payments for both the supply and sales functions of the Company, and both buyer and seller options. Multiple forecasted scenarios were evaluated which include (i) a minimum payment case, (ii) an expected payment case and (iii) a maximum payment case. The Company determined the potential deferred payment cash flows of Equipois and the Company based on each scenario. The cash flow payments were converted to a present value using a discount rate of 15 For the year ended December 31, 2016, the consideration payout calculated includes the $ 500 125 7.00 355 196 Amount Fixed assets $ 40 Intangible assets 1,610 Total identifiable assets acquired 1,650 Goodwill 189 Net assets acquired $ 1,839 The Company recorded $ 1,610 3 558 26 189 Accumulated Estimated Cost Amortization Net Useful Life Developed technology $ 1,160 $ (421) $ 739 3 yrs Customer relationships 70 (25) 45 3 yrs Customer trade name 380 (138) 242 3 yrs $ 1,610 $ (584) $ 1,026 The estimated future aggregate amortization expense is $ 537 489 Pro Forma Years ended December 31 2015 2014 Revenue $ 9,434 $ 5,449 Net loss $ (19,590) $ (33,978)

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following: ⋅ Level 1 ⋅ Level 2 ⋅ Level 3 Quoted Prices Significant in Active Other Significant Markets For Observable Unobservable Identical Items Inputs Inputs Total (Level 1) (Level 2) (Level 3) December 31, 2016 Liabilities Warrant liability $ 3,546 $ - $ - $ 3,546 Contingent consideration liability $ 217 $ - $ - $ 217 Contingent success fee liability $ 116 $ - $ - $ 116 December 31, 2015 Liabilities Warrant liability $ 9,195 $ - $ - $ 9,195 Contingent consideration liability $ 768 $ - $ - $ 768 During the years ended December 31, 2016 and 2015, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and the valuation techniques used did not change compared to the Company’s established practice. We measure our contingent consideration liability at fair value at each reporting period using significant unobservable inputs classified within Level 3 of the fair value hierarchy. We use a probability weighted value analysis as a valuation technique to convert future estimated cash flows to a single present value amount. The significant unobservable inputs used in the fair value measurements are sales projections over the earn-out period, and the probability outcome percentages assigned to each scenario. Significant increases or decreases to either of these inputs in isolation would result in a significantly higher or lower liability with a higher liability capped by the contractual maximum of the contingent earn-out obligation. Ultimately, the liability will be equivalent to the amount settled, and the difference between the fair value estimate and amount settled will be recorded in earnings. The amount settled that is less than or equal to the liability on the acquisition date is reflected as non-cash financing activities in our consolidated statements of cash flows. Any amount settled in excess of the liability on the acquisition date is reflected as non-cash operating activities. Any changes in the estimated fair value of our contingent consideration liabilities related to the time component of the present value calculation are reported in interest expense. Adjustments to the estimated fair value related to changes in all other unobservable inputs are reported in our statements of operations and comprehensive loss. Contingent Contingent Warrant Consideration Success Fee Liability Liability Liability Balance at December 31, 2015 $ 9,195 $ 768 $ - Reclassification of warrant liability to equity upon exercise of warrants (1,363) - - Gain on decrease in fair value of warrants issued with 2015 financing (4,286) - - Reclassification of contingent consideration liability to accrued liabilities - (355) - Gain on re-measurement of fair value of contingent consideration liability transferred to accrued liabilities - (196) - Fair value of contingent success fee related to long-term debt 116 Balance at December 31, 2016 $ 3,546 $ 217 $ 116 The warrants were valued at $ 9,195 4,286 Capitalization and Equity Structure – 2015 Warrants

Inventories, net

Inventories, net	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventories, net	6. Inventories, net December 31, 2016 2015 Raw materials $ 1,193 $ 783 Work in progress 198 336 Finished goods 267 19 1,658 1,138 Less: inventory reserve (102) (82) Inventories, net $ 1,556 $ 1,056

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment, net	7. Property and Equipment, net Estimated December 31, Life (Years) 2016 2015 Machinery and equipment 3-5 $ 3,432 $ 3,097 Computers and peripherals 3-7 564 460 Computer software 3-5 547 148 Leasehold improvement 5-10 625 625 Tools, molds, dies and jigs 5 50 37 Furniture, office and leased equipment 3-13 593 511 5,811 4,878 Accumulated depreciation and amortization (3,376) (2,253) Property and equipment, net $ 2,435 $ 2,625 Depreciation and amortization expense, including amortization of intangible assets, totaled $ 1,855 933 745

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2016
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Liabilities	8. Accrued Liabilities December 31, 2016 2015 Salaries, benefits and related expenses $ 2,349 $ 1,464 Maintenance 483 - Warranty expense 203 - Professional fees 56 257 Equipois earn-out 355 - Other 110 164 Total $ 3,556 $ 1,885 Maintenance and Warranty Sales of devices generally include an initial warranty for parts and services for one year in the U.S. and two years in Europe, the Middle East, and Africa. During the year ended December 31, 2016, the Company determined it had sufficient historical experience of warranty costs to estimate future warranty costs for devices sold. As a result, and beginning during the year ended December 31, 2016, a liability for the estimated cost of product warranty is established at the time revenue is recognized based on the historical experience of known product failure rates and expected material and labor costs to provide warranty services. From time to time, specific additional warranty accruals may be made if unforeseen technical problems arise. Alternatively, if estimates are determined to be greater than the actual amounts necessary, a portion of the liability may be reversed in future periods. Warranty costs are reflected in the consolidated statements of operations and comprehensive loss as a component of costs of revenue. 911 2016 Maintenance Warranty Total Balance at December 31, 2015 $ - $ - $ - Additions for estimated future expense 911 430 1,341 Incurred costs (428) (226) (654) Balance at December 31, 2016 $ 483 $ 204 $ 687 Current portion 483 203 686 Long-term portion - 1 1 Total $ 483 $ 204 $ 687 2015 Maintenance Warranty Total Balance at December 31, 2014 $ - $ 126 $ 126 Incurred costs - (126) 126 Balance at December 31, 2015 $ - $ - $ -

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Long-Term Debt	9. Long-Term Debt On December 30, 2016, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) that provided up to $ 10,000 7,000 3,000 15,000 , including proceeds of intellectual property, but expressly excluding intellectual property itself. Pursuant to the Loan Agreement, the proceeds from the Term Loans may only be used for working capital purposes and to fund general business requirements. The Term Loans will bear interest on the outstanding daily balance at a floating per annum rate equal to the 30 day U.S. LIBOR rate plus 5.41 The Company is required to pay accrued interest on the Term A Loan on the first day of each month through and including January 1, 2018 (or July 1, 2018, if the Term B Loan is drawn upon). Commencing on February 1, 2018 (or August 1, 2018, if the Term B Loan is drawn upon), the Company is required make equal monthly payments of principal, together with accrued and unpaid interest. The principal balance of the Term Loans amortizes ratably over 36 months (or 30 months, if the Term B Loan is drawn upon). The maturity of the Term Loans is January 1, 2021 3.5 The Company may elect to prepay a Term Loan at any time, in whole but not in part. If the Company prepays a Term Loan prior to December 30, 2017, it will owe a prepayment fee equal to 1.0 3.5 The Loan Agreement includes funding conditions, representations and warranties and covenants customary to similar credit facilities. In addition, the Company agreed to a liquidity covenant requiring that it maintain unrestricted cash and cash equivalents in accounts at Lender or subject to control agreements in favor of Lender in an amount equal to at least three months of “Monthly Cash Burn,” which is the Company’s average monthly net income (loss) for the trailing six-month period plus certain expenses and plus the average monthly principal due and payable on interest-bearing liabilities in the immediately succeeding three-month period. Such amount was determined to be $ 6,206 16,846 Company for the payment of money in an amount, individually or in the aggregate, of at least $250, or (9) any material misrepresentation or material misstatement with respect to any warranty or representation set forth in the Loan Agreement. On December 30, 2016, pursuant to the Loan Agreement, the Company entered into a Success Fee Agreement with the Lender under which the Company agreed to pay the Lender a $ 250 fee upon the first to occur of any of the following events: (a) a sale or other disposition by the Company of all or substantially all of its assets; (b) a merger or consolidation of the Company into or with another person or entity, where the holders of the Company’s outstanding voting equity securities immediately prior to such merger or consolidation hold less than a majority of the issued and outstanding voting equity securities of the successor or surviving person or entity immediately following the consummation of such merger or consolidation; or (c) the closing price per share for the Company’s common stock being $ 8.00 or more for five successive business days. The estimated fair value of the success fee was determined using the Binomial Lattice Model and was recorded as a discount to the debt obligation. The fair value of the contingent success fee is re-measured each reporting period with any adjustments in fair value being recognized in loss from operations. The success fee is classified as a liability on the consolidated balance sheets. At December 31, 2016, the carrying value of the contingent success fee liability was $ 116 The final payment fee, debt issuance costs, and fair value of the success fee combined with the stated interest result in an effective interest rate of 6.27 %. The final payment fee and debt issuance costs will be accreted and amortized, respectively, to interest expense using the effective interest method over the life of the loan. Period Amount 2017 $ - 2018 2,139 2019 2,333 2020 2,333 2021 195 Total principal payments 7,000 Less issuance costs & debt discount 211 Long-term debt, net $ 6,789

Lease and Note Obligations

Lease and Note Obligations	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Lease and Note Obligations	10. Lease and Note Obligations In November 2011, the Company entered into an operating lease agreement for its headquarters and manufacturing facility in Richmond, California. The lease term commenced in March 2012 and expires in May 2017, with one option to renew for an additional five years. In November 2016, the Company signed the five-year lease extension option for its Richmond headquarters. The option lease term will commence in June 2017 and expire in May 2022, which is included in the table below. The Company also leases nominal office space in Germany. In 2012, the Company entered into a note agreement in connection with the lease for its Richmond, California facility. The note, for an aggregate principal of $ 200 7 4 May 31, 2017 Commencing in August 2015, the Company entered into a long-term capital lease obligation for equipment. The aggregate principal of the lease is $ 166 4.7 3 July 1, 2020 Period Operating Leases Note Payable Capital Lease Total Minimum Payments 2017 $ 461 $ 20 $ 40 $ 60 2018 483 - 37 37 2019 494 - 37 37 2020 504 - 22 22 2021 429 - - - Thereafter 181 - - - Total minimum payments $ 2,552 20 136 156 Less interest (1) (11) (12) Present value minimum payments 19 125 144 Less current portion (19) (35) (54) Long-term portion $ - $ 90 $ 90 Rent expense under the Company’s operating leases was $ 400 342 343

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plan	The Company administers a 401(k) retirement plan (the “401(k) Plan”) in which all employees are eligible to participate. Each eligible employee may elect to contribute to the 401(k) Plan. During the years ended December 31, 2016 and 2015, the Company has made no matching contributions.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	12. Related Party Transactions The Company has license agreements and various collaboration agreements (see Note 16, Commitments and Contingencies 146 50 391 23 10

Capitalization and Equity Struc

Capitalization and Equity Structure	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Capitalization and Equity Structure	13. Capitalization and Equity Structure Reverse Stock Split After the close of the stock market on May 4, 2016, the Company effected a 1-for-7 reverse Summary The Company’s authorized capital stock at December 31, 2016 consisted of 71,429 10,000 21,894 Common Stock The holders of outstanding shares of common stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends at such times and in such amounts as the Board of Directors from time to time may determine. Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. There is no cumulative voting for the election of directors. The common stock is not entitled to pre-emptive rights and is not subject to conversion or redemption. Upon liquidation, dissolution or winding up of the Company, the assets legally available for distribution to stockholders are distributable ratably among the holders of the common stock after payment of liquidation preferences, if any, on any outstanding payment of other claims of creditors. Each outstanding share of common stock is duly and validly issued, fully paid, and non-assessable. 2016 Common Stock Offering On August 12, 2016, the Company issued 3,750 4.00 13,696 267 998 As discussed below, the Series A Convertible Preferred Stock issued in December 2015 (the “Preferred Shares”) and the common stock warrants issued in December 2015 (the “2015 Warrants”) included price-based anti-dilution provisions providing for the adjustment of the conversion price and the exercise price, as applicable, in the event the Company sells common stock or common stock equivalents (subject to exceptions for certain exempt issuances) at a price lower than the then-conversion price of the Preferred Shares or the then-exercise price of the 2015 Warrants. Because the sale price to the underwriters of the common stock in the August 2016 common stock offering was less than the then-conversion price of the Preferred Shares and the then-exercise price of the 2015 Warrants, there was an anti-dilution adjustment to the number of shares of common stock issuable upon conversion of the Preferred Shares and the exercise price of the 2015 Warrants was reduced, as discussed in more detail below. Preferred Stock The Company may issue shares of preferred stock from time to time in one or more series, each of which will have such distinctive designation or title as shall be determined by its Board of Directors and will have such voting powers, full or limited, or no voting powers, and such preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof, as shall be stated in such resolution or resolutions providing for the issue of such class or series of preferred stock as may be adopted from time to time by the Board of Directors. Convertible Preferred Stock On December 23, 2015, the Company entered into an agreement to issue 15 2,122 15,000 13,906 173 0.141 3,300 Conversion of the Preferred Shares triggers the amortization of the discount related to a beneficial conversion feature and to the 2015 Warrants. The terms of the Preferred Shares and 2015 Warrants included price-based anti-dilution provisions providing for the adjustment of the conversion price and the exercise price, as applicable, in the event the Company sold common stock or common stock equivalents (subject to exceptions for certain exempt issuances) at a price lower than the then-conversion price of the Preferred Shares or the then-exercise price of the 2015 Warrants. Because the sale price to the underwriters of the common stock in the August 2016 common stock offering was less than the conversion price of the Preferred Shares at the time, the conversion price of the Preferred Shares was adjusted downwards from $ 7.07 3.74 0.267 3 921 At December 31, 2015, 13 10 1,389 7.07 3 921 3.74 10,345 2 7.07 1,355 Warrants Exercise Term December 31, December 31, Source Price (Years) 2015 Exercised 2016 2015 Warrants $ 3.74 5 2,122 488 1,634 2014 PPO and Merger Placement agent warrants $ 7.00 5 426 - 426 Bridge warrants $ 7.00 3 371 - 371 PPO warrants $ 14.00 5 1,078 - 1,078 Pre 2014 warrants $ 9.66 various 88 - 88 4,085 488 3,597 2015 Warrants In connection with the December 2015 issuance of Preferred Shares discussed above, the Company issued 2015 Warrants to purchase up to an aggregate of 2,122 5 8.75 3.74 The terms of the 2015 Warrants are as follows: ⋅ Anti-Dilution Provision : The Warrants contain a “down round” anti-dilution adjustment provision, which provides that, solely during the period commencing on the date of the securities purchase agreement was executed in connection with the Financing and ending upon the closing of a financing resulting in aggregate proceeds to the Company of at least $ 10 ⋅ Put Option : While the Warrants are outstanding, if the Company enters into a Fundamental Transaction, defined as a merger, consolidation or similar transaction, the Company or any successor entity will, at the option of each Holder, exercisable at any time within 30 days after the consummation of the Fundamental Transaction, purchase the Warrant from the Holder exercising such option by paying to the Holder an amount of cash equal to the Black-Scholes Value of the remaining unexercised portion of such Holder’s Warrant on the date of the consummation of the Fundamental Transaction. ⋅ Call Option : Subject to certain conditions, the Company may call for cancellation of all or any portion of the unexercised Warrants. The consideration paid by the Company will be equal to the Black-Scholes Value of that portion of the Warrant called on the date the Company provides notice of its call. If the Company consummates a Fundamental Transaction (as described above) within six months after exercising its call option, and the consideration received by a holder of one share of common stock in such Fundamental Transaction is greater than the price per Warrant received by the Holder pursuant to the call, then the Company shall pay the Holder an amount equal to the difference between (x) the consideration received by a holder of common stock upon the Fundamental Transaction and (y) the price per Warrant paid in connection with the call, less the exercise price of the Warrant, payable in the same form as received by a holder of the common stock. If the Fundamental Transaction is a stock for stock merger, the Holder would receive shares of the successor entity valued at $ 1.75 ⋅ Cashless Exercise : If at the time of exercise there is no effective registration statement registering the shares underlying the Warrants, then the Warrants may be exercised on a cashless basis. The Warrants were valued at $ 11,700 487 The warrant liability is measured at fair value using certain estimated inputs, which are classified within Level 3 of the valuation hierarchy. These values are subject to a significant degree of judgment on our part. The Company’s common stock price represents a significant input that affects the valuation of the warrants. December 31, 2016 Current share price $ 3.98 Conversion price $ 3.74 Risk-free interest rate 1.70 % Expected term (years) 3.98 Volatility of stock 70 % The Company estimated the fair value of the warrant liability on December 31, 2015 by using a Binomial Lattice Model. The following assumptions were used in the Binomial Lattice Model to measure the fair value of the 2015 Warrants, including the embedded anti-dilution feature, as of December 31, 2015: December 31, 2015 Current share price $ 7.14 Conversion price $ 8.25 Risk-free interest rate 1.76 % Periodic rate 0.88 % Time to Maturity (years) 4.98 Volatility of stock 75 % 2014 PPO and Merger Warrants As discussed in Note 3, 2014 Merger, Offering and Other Related Transactions, 5,151 4,329 14.00 7.00 Dividend yield – Risk-free interest rate 0.60% - 1.73 % Share price at final valuation $ 1.51 Expected term (in years) 2.15- 4.80 Volatility 65% - 79 % As a result of the anti-dilution feature, the Company recorded a non-cash charge of $ 16,485 4,329 7.00 14.00 22,756 1,467 27,099 As discussed in Note 3 , 2014 Merger, Offering and Other Related Transactions 89 88 9.66

Employee Stock Options

Employee Stock Options	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Stock Options	14. Employee Stock Options In the first quarter of 2014, prior to the Merger, the Board of Directors and a majority of the stockholders adopted the 2014 Plan allowing for the issuance of 2,058 1,656 3,714 1,086 948 Under the terms of the 2014 Plan, the Board of Directors may award stock, options, or similar rights having either a fixed or variable price related to the fair market value of the shares and with an exercise or conversion privilege related to the passage of time, the occurrence of one or more events, or the satisfaction of performance criteria or other conditions or any other security with the value derived from the value of the shares. Such awards include stock options, restricted stock, restricted stock units, stock appreciation rights and dividend equivalent rights. The Board of Directors may grant stock options under the 2014 Plan at a price of not less than 100 110 Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life (Years) Value Outstanding as of December 31, 2015 1,963 $ 7.09 Granted 813 $ 5.40 Exercised (44) $ 2.51 Forfeited (224) $ 8.06 Expired (31) $ 9.39 Outstanding as of December 31, 2016 2,477 $ 6.50 7.46 $ 674 Vested and expected to vest at December 31, 2016 2,321 $ 6.49 7.34 $ 672 Exercisable as of December 31, 2016 1,262 $ 5.97 6.01 $ 659 In 2016, we received $ 110 103 3.52 2,456 As of December 31, 2016, total unrecognized compensation cost related to unvested stock options was $ 4,822 2.6 Shares Available For Grant Available as of December 31, 2015 1,506 Granted (813) Forfeited 224 Expired 31 Available as of December 31, 2016 948 Options Outstanding Options Exercisable Weighted-Average Weighted Weighted Range of Remaining Average Average Exercise Number of Contractual Life Exercise Number of Exercise Prices Shares (Years) Price Shares Price $0.28 - $0.49 106 1.89 $ 0.36 106 $ 0.36 $2.73 - $4.00 762 6.90 $ 3.61 465 $ 3.39 $4.67 - $7.42 876 8.03 $ 6.55 387 $ 6.81 $8.96 - $15.33 733 8.14 $ 10.33 304 $ 10.80 2,477 7.45 $ 6.50 1,262 $ 5.97 Years Ended December 31, 2016 2015 2014 Sales and marketing $ 677 $ 579 $ 345 Research and development 632 414 180 General and administrative 1,812 738 618 $ 3,121 $ 1,731 $ 1,143 In connection with the resignation of the Company’s then Chief Executive Officer in February 2016, the Company accelerated the vesting of options that would have vested in the subsequent twelve months and extended the exercise period of the resulting options from three months to six years. In addition, the Company extended the exercise period for an employee that was terminated in March 2016 from three months to one year. These modifications resulted in incremental stock-based compensation expense of $ 59 774 During the year ended December 31, 2014, due to a decline in the Company’s stock price following the Merger, options representing 122 14 24.99 45.50 15.33 411 The Company recognizes compensation expense using the straight-line method over the requisite service period. Years Ended December 31, 2016 2015 2014 Dividend yield — — — Risk-free interest rate 1.24% - 2.37 % 1.41% - 2.50 % 0.97% - 2.61 % Expected term (in years) 5.27-10 5.52-10 3-10 Volatility 77%-83 % 73%-76 % 66%-75 %

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	15. Income Taxes Years Ended December 31, 2016 2015 2014 Domestic $ (21,458) $ (19,918) $ (33,750) Foreign (2,012) 328 113 Loss before income taxes $ (23,470) $ (19,590) $ (33,637) The Company had no current or deferred federal and state income tax expense or benefit for the years ended December 31, 2016, 2015, and 2014 because the Company generated net operating losses, and currently management does not believe it is more likely than not that the net operating losses will be realized. The Company’s non-U.S. tax obligation is primarily for business activities conducted through the United Kingdom for which taxes included in other expense, net for the years ended December 31, 2016, 2015, and 2014 were immaterial and accordingly, such amounts were excluded from the following tables. Years Ended December 31, 2016 2015 2014 Federal tax at statutory rate 34.0 % 34.0 % 34.0 % State tax, net of federal tax effect - - 1.5 R&D credit 0.9 0.5 0.3 Change in valuation allowance (40.8) (38.4) (18.9) Non- deductible expenses (0.2) (1.0) (.2) Unrealized (gain) loss on warrant 6.2 4.3 Foreign (0.4) 0.5 (0.1) Other 0.3 0.1 0.1 Total tax expense - % - % - % December 31, 2016 2015 Deferred tax assets: Depreciation and other $ 61 $ - Net operating loss carryforwards 35,647 26,826 Unused R& D tax credits 872 530 Accruals & reserves 951 317 Deferred Revenue 246 693 Stock Compensation 2,430 1,222 Other 86 43 Deferred tax liabilities: Depreciation and other - (220) Prepaid expenses (168) (113) Less: Valuation allowance (40,125) (29,298) Net deferred tax asset (liability) $ - $ - The Company’s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of the Company’s net deferred tax assets. The Company primarily considered such factors as the Company’s history of operating losses; the nature of the Company’s deferred tax assets and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. At present, the Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a full valuation allowance was established and no deferred tax assets were shown in the accompanying balance sheets. The valuation allowance increased by $ 10,827 7,983 As of December 31, 2016 the Company had federal net operating loss carryforwards of $ 93,749 818 As of December 31, 2016, the Company had state net operating loss carryforwards of $ 76,263 524 As of December 31, 2016, the Company had foreign net operating loss carryforwards of $ 2,012 As of December 31, 2016, $ 1,684 657 Utilization of the Company’s net operating losses and credit carryforwards may be subject to annual limitations in the event of a Section 382 ownership change. Such future limitations could result in the expiration of net operating losses and credit carryforwards before utilization as a result of such an ownership change. Balance at December 31, 2013 $ 93 Increase of unrecognized tax benefits taken in prior years 4 Increase of unrecognized tax benefits related to current year 46 Balance at December 31, 2014 143 Decrease of unrecognized tax benefits taken in prior years (19) Increase of unrecognized tax benefits related to current year 75 Balance at December 31, 2015 199 Increase of unrecognized tax benefits taken in prior years 4 Increase of unrecognized tax benefits related to current year 132 Balance at December 31, 2016 $ 335 If the Company eventually is able to recognize these uncertain tax positions, the unrecognized tax benefits would not reduce the effective tax rate if the Company is applying a full valuation allowance against the deferred tax assets, as is the Company’s current policy. The Company had not incurred any material tax interest or penalties as of December 31, 2016. The Company does not anticipate any significant change within 12 months of this reporting date of its uncertain tax positions. The Company is subject to taxation in the United States, the United Kingdom, Germany, and various states jurisdictions. There are no other ongoing examinations by taxing authorities at this time. The Company’s tax years 2007

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Contingencies In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not have a material adverse effect on the Company’s consolidated financial statements. Material Contracts The Company enters into various license, research collaboration and development agreements which provide for payments to the Company for government grants, fees, cost reimbursements typically with a markup, technology transfer and license fees, and royalty payments on sales. The Company has two license agreements to maintain exclusive rights to patents. The Company is also required to pay 1 21 1 50 In connection with acquisition of Equipois, the Company assumed the rights and obligations of Equipois under a license agreement with Garrett Brown, the developer of certain intellectual property related to mechanical balance and support arm technologies, which grants us an exclusive license with respect to the technology and patent rights for certain fields of use. Pursuant to the terms of the license agreement, the Company will be required to pay Mr. Brown a single-digit royalty on net receipts, subject to a $ 50 Payments Due By Period Less than Total one year 1-3 Years 4-5 Years After 5 Years Term loan $ 8,345 $ 397 $ 7,508 $ 440 $ - Facility operating lease 2,552 461 1,481 610 - Capital lease 136 40 96 - - Leasehold improvement loan 20 20 - - - Total $ 11,053 $ 918 $ 9,085 $ 1,050 $ - U.S. Food and Drug Administration Clearance On April 4, 2016, the Company received clearance from the U.S. Food and Drug Administration (“FDA”) to market its Ekso GT robotic exoskeleton for use in the treatment of individuals with hemiplegia due to stroke, individuals with spinal cord injuries at levels T4 to L5, and individuals with spinal cord injuries at levels of T3 to C7 (ASIA D), in accordance with the device’s labeling. On July 19, 2016, the Company received clearance from the FDA to expand/clarify the indications and labeling to expressly include individuals with hemiplegia due to stroke who have upper extremity function of at least 4/5 in only one arm. The Company’s prior cleared indications for use statement required that individuals with hemiplegia due to stroke have upper extremity function of at least 4/5 in both arms. The Company believes that prior to April 4, 2016, the Company’s Ekso GT robotic exoskeleton had been appropriately marketed in the United States as a Class I 510(k) exempt Powered Exercise Equipment device since February 2012. On June 26, 2014, the FDA announced the creation of a new product classification for Powered Exoskeleton devices. On October 21, 2014, the FDA published the summary for the new Powered Exoskeleton classification and designated it as being Class II, which requires the clearance of a 510(k) notice. On October 21, 2014, concurrent with the FDA’s publication of the reclassification of Powered Exoskeleton devices, the FDA issued the Company an “Untitled Letter” which informed the Company in writing of the agency’s belief that this new product classification applied to the Ekso GT device. On December 24, 2014, the Company filed a 510(k) notice for the Ekso robotic exoskeleton which was accepted by the FDA for substantive review on July 29, 2015. As discussed above, the Company received FDA clearance to market the Ekso GT in accordance with the device’s labeling on April 4, 2016. From September 2, 2015 to September 11, 2015, the Division of Bioresearch Monitoring Center for Devices and Radiological Health of the FDA conducted an inspection of the Company’s facility in Richmond, California. At the conclusion of the inspection, the FDA issued a Form FDA 483 with four observations. These observations were inspectional and did not represent a final FDA determination of non-compliance. The observations pertained to informed consent requirements, reporting of adverse results and records maintenance. On October 2, 2015, the Company responded to the FDA describing the corrective and preventive actions that the Company had implemented and continued to implement to address the FDA’s concerns. On March 30, 2016, the FDA accepted the Company’s corrective actions for the Form 483 observations that were generated during the FDA’s inspection.

Segment Disclosures

Segment Disclosures	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Segment Disclosures	17. Segment Disclosures During the third quarter of 2016, the Company determined industrial sales to be a reportable segment as a result of progress in commercialization and sales of its industrial devices. We have recast certain prior period amounts to conform to the way we internally manage and monitor segment performance. The Company has three reportable segments, Medical Devices, Industrial Sales, and Engineering Services. The Medical Devices segment designs and engineers technology, and commercializes, manufactures, and sells exoskeletons for applications in the medical markets. The Industrial Sales segment designs, engineers, commercializes, and sells exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. Engineering Services generates revenue principally from collaborative research and development service arrangements, technology license agreements, and government grants where the Company uses its robotics domain knowledge in bionic exoskeletons to bid on and procure contracts and grants from entities such as the National Science Foundation and the Defense Advanced Research Projects Agency. The Company evaluates performance and allocates resources based on segment gross profit margin. The reportable segments are each managed separately because they serve distinct markets, and one segment provides a service and the others manufacture and distribute unique products. The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated. Medical Industrial Engineering Devices Sales Services Total Year ended December 31, 2016 Revenue $ 12,081 $ 1,253 $ 887 $ 14,221 Cost of revenue 9,767 948 559 11,274 Gross profit $ 2,314 $ 305 $ 328 $ 2,947 Year ended December 31, 2015 Revenue $ 4,252 $ - $ 4,409 $ 8,661 Cost of revenue 3,926 - 3,556 7,482 Gross profit $ 326 $ - $ 853 $ 1,179 Year ended December 31, 2014 Revenue $ 2,924 $ - $ 2,403 $ 5,327 Cost of revenue 2,048 - 1,720 3,768 Gross profit $ 876 $ - $ 683 $ 1,559 Years Ended December 31 2016 2015 2014 United States $ 9,042 $ 6,382 $ 3,873 All Other 5,179 2,279 1,454 $ 14,221 $ 8,661 $ 5,327

Quarterly Data (Unaudited)

Quarterly Data (Unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information	18. Quarterly Data (Unaudited) Quarter Ended March 31 June 30 September 30 December 31 2016 Revenue $ 8,486 $ 1,552 $ 1,596 $ 2,587 Gross profit 1,498 203 403 843 Net loss (3,651) (5,765) (8,478) (5,576) Net loss applicable to common shareholders (6,775) (9,970) (11,494) (5,576) Basic net loss per share (1) (0.44) (0.61) (0.60) (0.29) Diluted net loss per share (1) $ (0.44) $ (0.61) $ (0.60) $ (0.35) 2015 Revenue $ 1,689 $ 2,114 $ 2,915 $ 1,943 Gross profit 403 502 468 (194) Net income (loss) (4,115) (5,645) (5,185) (4,645) Net loss applicable to common shareholders (4,115) (5,645) (5,185) (9,300) Basic and diluted net loss per share (1) $ (0.28) $ (0.39) $ (0.35) $ (0.63) (1) Quarterly net loss per common share amounts may not total to the annual amounts due to rounding and the changes in the number of weighted common shares outstanding and included in the calculation of basic and diluted common shares.

Summary of Significant Accoun26

Summary of Significant Accounting Policies and Estimates (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). All significant intercompany transactions and balances have been eliminated in consolidation. Certain reclassifications have been made to conform to the current period’s presentation. All common share and per share amounts have been adjusted to reflect the one-for-seven reverse stock split completed on May 4, 2016. See Note 13, Capitalization and Equity Structure – Reverse Stock Split
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of associated costs, valuation of acquired intangible assets and goodwill, useful lives assigned to long-lived assets, realizability of deferred tax assets, valuation of common and preferred stock warrants, the valuation of options, and contingencies. Actual results could differ from those estimates.
Foreign Currency Translation	Foreign Currency Translation The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income (loss) as a component of stockholders’ equity. Where the U.S. dollar is the functional currency, re-measurement adjustments are recorded in other comprehensive income (loss), net in the accompanying consolidated statements of operations and comprehensive loss. Gains and losses realized from transactions, including related party balances not considered permanent investments, that are denominated in currencies other than an entity’s functional currency are included in other expense
Comprehensive Income / (Loss)	Accumulated Other Comprehensive Income (Loss) Accumulated other comprehensive income (loss) reported on our consolidated balance sheets consists of foreign currency translation adjustments. Foreign Currency Translation Balance at December 31, 2015 $ (1) Other comprehensive loss before reclassification 80 Amounts reclassified from accumulated other comprehensive income (loss) - Net current period other comprehensive income 80 Balance at December 31, 2016 $ 79
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with a maturity of three months or less to be cash equivalents. The Company’s cash is deposited in bank accounts with the Company’s primary cash management bank. The Company places its cash and cash equivalents in highly liquid instruments with, and in the custody of, financial institutions with high credit ratings. The Company did not have any cash equivalents or investments in money market funds as of December 31, 2016 and 2015.
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains our cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable. Accounts receivable are derived from the sale of products shipped and services performed for customers located in the U.S. and throughout the world. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for credit losses, as needed. The Company has not experienced material losses related to accounts receivable during the years ended December 31, 2016 and December 31, 2015. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling foreign contracts. At December 31, 2016, the Company had three customers with accounts receivable balances totaling 10 18 16 11 10 22 11 For the year ended December 31, 2016, the Company had no customers with billed revenue of 10 33 12
Inventories, net	Inventories, net Inventories are recorded at the lower of cost or market value. Cost is principally determined using the average cost method. Parts from vendors are received and recorded as raw material. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress (“WIP”). Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge to the consolidated statements of operations and comprehensive loss
Property and Equipment	Property and Equipment, net Property and equipment are stated at cost less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally ranging from three to thirteen years. Leasehold improvements are amortized over the shorter of the estimated useful life of ten years or the related term of the lease. The costs of repairs and maintenance are expensed when incurred, while expenditures for refurbishments and improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized. When assets are retired or sold, the asset cost and related accumulated depreciation or amortization are removed from the accompanying consolidated balance sheets, with any gain or loss reflected in the accompanying consolidated statements of operations and comprehensive loss. The Company has evaluated its lease obligations and does not have any material asset retirement obligations.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that their carrying value may not be recoverable from the estimated future cash flows expected to result from their use or eventual disposition. If estimates of future undiscounted net cash flows are insufficient to recover the carrying value of the assets, the Company will record an impairment loss in the amount by which the carrying value of the assets exceeds the fair value. If the assets are determined to be recoverable, but the useful lives are shorter than originally estimated, the Company will depreciate or amortize the net book value of the assets over the newly determined remaining useful lives. None of the Company’s property and equipment or intangible assets were impaired as of December 31, 2016 and 2015. Accordingly, no impairment loss has been recognized in the years ended December 31, 2016, 2015, and 2014.
Goodwill	Goodwill The Company records goodwill when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. We perform an annual impairment assessment in the fourth quarter of each year, or more frequently if indicators of potential impairment exist, which includes evaluating qualitative and quantitative factors to assess the likelihood of an impairment of goodwill. We perform impairment tests using a fair value approach when necessary. None of the Company’s goodwill was impaired as of December 31, 2016 and 2015. Accordingly, no impairment loss has been recognized in the years ended December 31, 2016, 2015, and 2014. For further discussion of goodwill, see Note 4 Equipois Acquisition
Convertible Instruments	Convertible Instruments We account for hybrid contracts that feature conversion options in accordance with generally accepted accounting principles in the United States. Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging Activities Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument. We account for convertible instruments when we have determined that the embedded conversion options should not be bifurcated from their host instruments, in accordance with ASC 470-20, Debt with Conversion and Other Options We also follow ASC 480-10, Distinguishing Liabilities from Equity
Warrants Issued in Connection with Financings	We generally account for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that we may need to settle the warrants in cash. For warrants where there is a possibility that we may have to settle the warrants in cash, we estimate the fair value of the issued warrants as a liability at each reporting date and record changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. model Option Pricing model The Company’s common stock price represents a significant input that affects the valuation of the warrants
Business Combinations	Business Combinations We account for business combinations under the acquisition method of accounting in accordance with ASC 805, Business Combinations Contingent consideration, if any, is recorded at the acquisition date based upon the estimated fair value of the contingent payments. The fair value of the contingent consideration is re-measured each reporting period with any adjustments in fair value being recognized in loss from operations. The purchase price in excess of the fair value of the tangible and identified intangible assets acquired less liabilities assumed is recognized as goodwill.
Going Concern	Going Concern We assess our ability to continue as a going concern at every interim and annual period in accordance with ASC 205-40. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The ability to meet our obligations as they come due and the attainment of sustainable profitability and positive cash flow from operations is dependent on certain future events. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. We evaluate whether it is probable that our plans to mitigate those conditions will alleviate that substantial doubt at every interim and annual period and disclose the conditions giving rise to substantial doubt and the results of our evaluation.
Deferred Rent	Deferred Rent Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis over the life of the lease.
Revenue and Cost of Revenue Recognition	Revenue and Cost of Revenue Recognition The Company recognizes revenue when the four basic criteria of revenue recognition are met: · Persuasive evidence of an arrangement exists. Customer contracts and purchase orders are generally used to determine the existence of an arrangement. · The transfer of technology or products has been completed or services have been rendered. Evidence of shipment or customer acceptance, when applicable, is used to verify delivery. · The sales price is fixed or determinable. The Company assesses whether the cost is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. · Collectability is reasonably assured. The Company assesses collectability based primarily on the creditworthiness of the customer as determined by credit checks and analysis as well as the customer’s payment history. When collaboration, other research arrangements, and product sales include multiple-element revenue arrangements, we account for these transactions by determining the elements, or deliverables, included in the arrangement and determining which deliverables are separable for accounting purposes. We consider delivered items to be separable if the delivered item(s) have stand-alone value to the customer and delivery or performance of the undelivered item is considered probable and substantially in control of the vendor. Medical Device Revenue and Cost of Revenue Recognition The Company builds medical device robotic exoskeletons for sale and capitalizes into inventory materials, direct and indirect labor and overhead in connection with manufacture and assembly of these units. When the Company brought its first version medical device to market in 2012, the Company could not be certain as to the costs it would incur to support, maintain, service, and upgrade these early stage devices. Primarily for this reason, prior to January 1, 2016, the sale of a device, associated software, initial training, and extended support and maintenance were deemed as a single unit of accounting due to the uncertainty of the Company’s follow-up maintenance and upgrade expenses, which were forecast to extend over three years. Accordingly, the revenue from the sales of the device and associated cost of revenue were deferred at the time of shipment. Upon completion of training, the amount of the arrangements were recognized as revenue and cost of revenue over a three year period on a straight line basis, while all service expenses, whether or not covered by the Company’s original warranty, extended warranty contracts, or neither, were recognized as incurred. Effective January 1, 2016, the Company determined it had established (i) separate individual pricing for training, extended warranty coverage, and out-of-contract service or repairs, (ii) sufficient historical evidence of customer buying patterns for extended warranty and maintenance coverage, and (iii) a basis for estimating and recording warranty and service costs to allow the Company to separate its multiple element arrangements into two distinct units of accounting: (1) the device, associated software, original manufacturer warranty and training if required, and (2) extended support and maintenance. As a result, in the first quarter of 2016, the Company began to recognize revenue related to its sales transactions on a multiple element approach in which revenue is recognized upon the delivery of the separate elements to the customer. Revenue relating to the undelivered elements is deferred using the relative selling price method, which allocates revenue to each element using the estimated selling prices for the deliverables when vendor-specific objective evidence or third-party evidence is not available. For sales on or after January 1, 2016, revenue and associated cost of revenue of medical devices is recognized when delivered, or training has been completed, if required. Revenue for extended maintenance and support agreements is recognized on a straight line basis over the contractual term of the agreement, which typically ranges from one to four years. As a result of this change, the Company recognized medical device revenue previously deferred at December 31, 2015 of $ 6,517 4,159 2,358 , or $0.13 per share, 212 911 Industrial Sales Revenue and Cost of Revenue The Company builds industrial exoskeletons for sale and capitalizes into inventory materials, direct and indirect labor, and overhead in connection with the manufacture and assembly of these units. No right of return exists on sales of industrial exoskeletons. We assess collectability at the time of the sale and if collectability is not reasonably assured, the sale is deferred and not recognized until collectability is probable or payment is received. Typically, where product is produced and sold in the same country, title and risk of ownership transfer when the product is shipped. Products that are exported from a country for sale typically pass title and risk of ownership at the border of the destination country. Because our industrial products are produced in the U.S., title and risk of ownership generally transfer when the product is shipped, if shipped to a customer in the U.S. If we sell products to customers outside the U.S., title and risk of ownership is generally transferred at the border of the destination country. Engineering Services Revenue and Cost of Revenue Collaborative arrangements typically consist of cost reimbursements for specific engineering and development spending, and future product royalty payments. Cost reimbursements for engineering and development spending are recognized as the related project labor hours are incurred in relation to all labor hours and when collectability is reasonably assured. Amounts received in advance are recorded as deferred revenue until the technology is transferred, services are rendered, or milestones are reached. Product royalty payments are recorded when earned under the arrangement. Government grants, which support the Company’s research efforts in specific projects, generally provide for reimbursement of approved costs as defined in the notices of grant awards. Grant revenue is recognized as the associated project labor hours are incurred in relation to total labor hours. There are some grants, such as the National Science Foundation grants, of which the Company draws upon and spends based on budgets preapproved by the grantor. The cost of engineering services revenue includes payroll and benefits, subcontractor expenses and materials. All costs related to engineering services are expensed as incurred and reported as cost of revenue.
Deferred Revenues	Deferred Revenues In connection with the Company’s medical device sales and research services, the Company often receives cash payments before its earnings process is complete. In these instances, the Company records the payments as customer deposits until a device is shipped to the customer, or as customer advances in the case of research services until the earnings process is achieved. In both cases, the cash received is recorded as a component of deferred revenue. December 31, 2016 2015 Customer deposits and advances $ 47 $ 48 Deferred medical device revenues - 7,388 Deferred rental income 60 71 Deferred extended maintenance and support 1,523 1,066 Total deferred revenues 1,630 8,573 Less current portion (825) (3,960) Deferred revenues, non-current $ 805 $ 4,613 Deferred medical device unit costs $ - $ 4,590 Less current portion - (2,088) Deferred cost of revenue, non-current $ - $ 2,502
Research and Development	Research and Development Research and development costs consist of costs incurred for internal research and development activities. These costs primarily include salaries and other personnel-related expenses, contractor fees, facility costs, supplies, and depreciation of equipment associated with the design and development of new products prior to the establishment of their technological feasibility. Such costs are expensed as incurred.
Advertising Costs	Advertising Costs Advertising costs are recorded in sales and marketing expense as incurred. Advertising expense was $ 104 25 1
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, income tax expense or benefit is recognized for the amount of taxes payable or refundable for the current year and for deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company's consolidated financial statements or tax returns. The Company accounts for any income tax contingencies in accordance with accounting guidance for income taxes. The measurement of current and deferred tax assets and liabilities is based on provisions of currently enacted tax laws. The effects of any future changes in tax laws or rates have not been considered. For the preparation of the Company's consolidated financial statements included herein, the Company estimates its income taxes and tax contingencies in each of the tax jurisdictions in which it operates prior to the completion and filing of its tax returns. This process involves estimating actual current tax expense together with assessing temporary differences resulting from differing treatment of items, such as deferred revenue, for tax and accounting purposes. These differences result in net deferred tax assets and liabilities. The Company must then assess the likelihood that the deferred tax assets will be realizable, and to the extent they believe that realizability is not likely, the Company must establish a valuation allowance. In assessing the need for any additional valuation allowance, the Company considers all the evidence available to it, both positive and negative, including historical levels of income, legislative developments, expectations and risks associated with estimates of future taxable income, and ongoing prudent and feasible tax planning strategies.
Stock-based Compensation	Stock-based Compensation The Company measures stock-based compensation expense for all stock-based awards made to employees and directors based on the estimated fair value of the award on the date of grant using the Black-Scholes option pricing model and recognizes the fair value on a straight-line basis over the requisite service periods of the awards. Stock-based awards made to non-employees are measured and recognized based on the estimated fair value on the vesting date and are re-measured at each reporting period. The Company’s determination of the fair value of stock-based awards on the date of grant using the Black-Scholes option pricing model is affected by the Company’s stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to the Company’s expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Because there is insufficient information available to estimate the expected term of the stock-based awards, the Company adopted the simplified method of estimating the expected term pursuant to SEC Staff Accounting Bulletin Topic 14. On this basis, the Company estimated the expected term of options granted by taking the average of the vesting term and the contractual term of the option. The Company has, from time to time, modified the terms of its stock options to employees. The Company accounts for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification.
Net Loss Per Share of Common Stock	Net Loss Per Share of Common Stock Years ended December 31, 2016 (1) 2015 2014 Numerator: Net loss applicable to common stockholders $ (33,815) $ (24,245) $ (33,769) Adjustment for gain on fair value of warrant liability (4,286) (2,505) - Adjusted net loss used for dilution calculation $ (38,101) $ (26,750) $ (33,769) Denominator Weighted-average number of shares outstanding 18,126 14,606 11,181 Effect of potential dilutive shares 496 3 - Dilutive weighted-average number of shares outstanding 18,622 14,609 11,181 Net loss per share applicable to common stockholders Basic $ (1.87) $ (1.66) $ (3.02) Diluted $ (2.05) $ (1.83) $ (3.02) (1) Recognition of previously deferred revenue and cost of goods in the year ended December 31, 2016 reduced net loss applicable to common stockholders by $2,358, or $ 0.13 Note 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates – Medical Device Revenue and Cost of Revenue Recognition Years ended December 31, 2016 2015 2014 Options to purchase common stock 2,477 1,963 1,542 Warrants for common stock 1,963 1,963 1,971 Common stock issuable upon conversion of preferred shares - 1,876 - Total common stock equivalents 4,440 5,802 3,513
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements – Going Concern In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs 95 In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09 Compensation – Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting so as to more closely align compensation expense to services provided In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments

Summary of Significant Accoun27

Summary of Significant Accounting Policies and Estimates (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The change in accumulated other comprehensive income (loss) presented on the consolidated balance sheets for the year ended December 31, 2016, is reflected in the table below net of tax: Foreign Currency Translation Balance at December 31, 2015 $ (1) Other comprehensive loss before reclassification 80 Amounts reclassified from accumulated other comprehensive income (loss) - Net current period other comprehensive income 80 Balance at December 31, 2016 $ 79
Schedule of Customer Deposits, Advances, Deferred Revenues, and Deferred Unit Costs	Deferred revenues and deferred cost of revenues consisted of the following: December 31, 2016 2015 Customer deposits and advances $ 47 $ 48 Deferred medical device revenues - 7,388 Deferred rental income 60 71 Deferred extended maintenance and support 1,523 1,066 Total deferred revenues 1,630 8,573 Less current portion (825) (3,960) Deferred revenues, non-current $ 805 $ 4,613 Deferred medical device unit costs $ - $ 4,590 Less current portion - (2,088) Deferred cost of revenue, non-current $ - $ 2,502
Schedule of basic and diluted net income (loss) per share	Years ended December 31, 2016 (1) 2015 2014 Numerator: Net loss applicable to common stockholders $ (33,815) $ (24,245) $ (33,769) Adjustment for gain on fair value of warrant liability (4,286) (2,505) - Adjusted net loss used for dilution calculation $ (38,101) $ (26,750) $ (33,769) Denominator Weighted-average number of shares outstanding 18,126 14,606 11,181 Effect of potential dilutive shares 496 3 - Dilutive weighted-average number of shares outstanding 18,622 14,609 11,181 Net loss per share applicable to common stockholders Basic $ (1.87) $ (1.66) $ (3.02) Diluted $ (2.05) $ (1.83) $ (3.02) (1) Recognition of previously deferred revenue and cost of goods in the year ended December 31, 2016 reduced net loss applicable to common stockholders by $2,358, or $ 0.13 Note 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates – Medical Device Revenue and Cost of Revenue Recognition
Schedule of Antidilutive Securities	The following potential dilutive securities were excluded from the computation of diluted net loss per share because including them would have been anti-dilutive: Years ended December 31, 2016 2015 2014 Options to purchase common stock 2,477 1,963 1,542 Warrants for common stock 1,963 1,963 1,971 Common stock issuable upon conversion of preferred shares - 1,876 - Total common stock equivalents 4,440 5,802 3,513

Equipois Acquisition (Tables)

Equipois Acquisition (Tables)	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Summary of Total Purchase Price	The total purchase price is summarized as follows: Amount Stock consideration (112 shares) $ 1,071 Estimated contingent consideration 768 Total purchase price $ 1,839
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the fair values of the assets acquired as of the acquisition date: Amount Fixed assets $ 40 Intangible assets 1,610 Total identifiable assets acquired 1,650 Goodwill 189 Net assets acquired $ 1,839
Schedule of Acquired Indefinite-lived Intangible Assets by Major Class	Acquired intangible assets as of December 31, 2016 were as follows: Accumulated Estimated Cost Amortization Net Useful Life Developed technology $ 1,160 $ (421) $ 739 3 yrs Customer relationships 70 (25) 45 3 yrs Customer trade name 380 (138) 242 3 yrs $ 1,610 $ (584) $ 1,026
Business Acquisition, Pro Forma Information	The following unaudited pro forma financial information reflects the Company’s consolidated statement of operations as if the acquisition of Equipois had taken place on January 1, 2014. The pro forma information includes adjustments for royalty revenue, impact from the Supply Agreement, and the amortization of intangible assets. The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transaction been effected on the assumed date. Years ended December 31 2015 2014 Revenue $ 9,434 $ 5,449 Net loss $ (19,590) $ (33,978)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The Company’s fair value hierarchies for its financial assets and liabilities which require fair value measurement on a recurring basis are as follows: Quoted Prices Significant in Active Other Significant Markets For Observable Unobservable Identical Items Inputs Inputs Total (Level 1) (Level 2) (Level 3) December 31, 2016 Liabilities Warrant liability $ 3,546 $ - $ - $ 3,546 Contingent consideration liability $ 217 $ - $ - $ 217 Contingent success fee liability $ 116 $ - $ - $ 116 December 31, 2015 Liabilities Warrant liability $ 9,195 $ - $ - $ 9,195 Contingent consideration liability $ 768 $ - $ - $ 768
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table sets forth a summary of the changes in the fair value of Company’s Level 3 financial liabilities during the year ended December 31, 2016, which were measured at fair value on a recurring basis: Contingent Contingent Warrant Consideration Success Fee Liability Liability Liability Balance at December 31, 2015 $ 9,195 $ 768 $ - Reclassification of warrant liability to equity upon exercise of warrants (1,363) - - Gain on decrease in fair value of warrants issued with 2015 financing (4,286) - - Reclassification of contingent consideration liability to accrued liabilities - (355) - Gain on re-measurement of fair value of contingent consideration liability transferred to accrued liabilities - (196) - Fair value of contingent success fee related to long-term debt 116 Balance at December 31, 2016 $ 3,546 $ 217 $ 116

Inventories, net (Tables)

Inventories, net (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventories consist of the following: December 31, 2016 2015 Raw materials $ 1,193 $ 783 Work in progress 198 336 Finished goods 267 19 1,658 1,138 Less: inventory reserve (102) (82) Inventories, net $ 1,556 $ 1,056

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, net	Property and equipment, net consisted of the following: Estimated December 31, Life (Years) 2016 2015 Machinery and equipment 3-5 $ 3,432 $ 3,097 Computers and peripherals 3-7 564 460 Computer software 3-5 547 148 Leasehold improvement 5-10 625 625 Tools, molds, dies and jigs 5 50 37 Furniture, office and leased equipment 3-13 593 511 5,811 4,878 Accumulated depreciation and amortization (3,376) (2,253) Property and equipment, net $ 2,435 $ 2,625

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following: December 31, 2016 2015 Salaries, benefits and related expenses $ 2,349 $ 1,464 Maintenance 483 - Warranty expense 203 - Professional fees 56 257 Equipois earn-out 355 - Other 110 164 Total $ 3,556 $ 1,885
Reconciliation of Changes in Maintenance and Warranty Liabilities	911 2016 Maintenance Warranty Total Balance at December 31, 2015 $ - $ - $ - Additions for estimated future expense 911 430 1,341 Incurred costs (428) (226) (654) Balance at December 31, 2016 $ 483 $ 204 $ 687 Current portion 483 203 686 Long-term portion - 1 1 Total $ 483 $ 204 $ 687 2015 Maintenance Warranty Total Balance at December 31, 2014 $ - $ 126 $ 126 Incurred costs - (126) 126 Balance at December 31, 2015 $ - $ - $ -

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Maturities of Long-term Debt	The following table presents scheduled principal payments of our long-term debt as of December 31, 2016: Period Amount 2017 $ - 2018 2,139 2019 2,333 2020 2,333 2021 195 Total principal payments 7,000 Less issuance costs & debt discount 211 Long-term debt, net $ 6,789

Lease and Note Obligations (Tab

Lease and Note Obligations (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Maturities of Future Obligations	Period Operating Leases Note Payable Capital Lease Total Minimum Payments 2017 $ 461 $ 20 $ 40 $ 60 2018 483 - 37 37 2019 494 - 37 37 2020 504 - 22 22 2021 429 - - - Thereafter 181 - - - Total minimum payments $ 2,552 20 136 156 Less interest (1) (11) (12) Present value minimum payments 19 125 144 Less current portion (19) (35) (54) Long-term portion $ - $ 90 $ 90

Capitalization and Equity Str35

Capitalization and Equity Structure (Tables)	12 Months Ended
	Dec. 31, 2016
Schedule of Warrant share activity	Exercise Term December 31, December 31, Source Price (Years) 2015 Exercised 2016 2015 Warrants $ 3.74 5 2,122 488 1,634 2014 PPO and Merger Placement agent warrants $ 7.00 5 426 - 426 Bridge warrants $ 7.00 3 371 - 371 PPO warrants $ 14.00 5 1,078 - 1,078 Pre 2014 warrants $ 9.66 various 88 - 88 4,085 488 3,597
Schedule of assumption used in valuation	Dividend yield – Risk-free interest rate 0.60% - 1.73 % Share price at final valuation $ 1.51 Expected term (in years) 2.15- 4.80 Volatility 65% - 79 %
Warrant [Member]
Schedule of assumption used in valuation	The Company estimated the fair value of the warrant liability on December 31, 2016 by using a Black-Scholes Option Pricing Model, as the anti-dilution provision was no longer in effect. The following assumptions were used in the Black-Scholes Option Pricing Model to measure the fair value of the 2015 Warrants as of December 31, 2016: December 31, 2016 Current share price $ 3.98 Conversion price $ 3.74 Risk-free interest rate 1.70 % Expected term (years) 3.98 Volatility of stock 70 % The Company estimated the fair value of the warrant liability on December 31, 2015 by using a Binomial Lattice Model. The following assumptions were used in the Binomial Lattice Model to measure the fair value of the 2015 Warrants, including the embedded anti-dilution feature, as of December 31, 2015: December 31, 2015 Current share price $ 7.14 Conversion price $ 8.25 Risk-free interest rate 1.76 % Periodic rate 0.88 % Time to Maturity (years) 4.98 Volatility of stock 75 %

Employee Stock Options (Tables)

Employee Stock Options (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Option Activity	A summary of the option activity as of December 31, 2016 and changes during the fiscal year then ended is presented below: Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life (Years) Value Outstanding as of December 31, 2015 1,963 $ 7.09 Granted 813 $ 5.40 Exercised (44) $ 2.51 Forfeited (224) $ 8.06 Expired (31) $ 9.39 Outstanding as of December 31, 2016 2,477 $ 6.50 7.46 $ 674 Vested and expected to vest at December 31, 2016 2,321 $ 6.49 7.34 $ 672 Exercisable as of December 31, 2016 1,262 $ 5.97 6.01 $ 659
Schedule of Shares available for future grant	Shares available for future grant under the 2014 Plan is as follows for the year ended December 31, 2016: Shares Available For Grant Available as of December 31, 2015 1,506 Granted (813) Forfeited 224 Expired 31 Available as of December 31, 2016 948
Summary of information about stock options outstanding	Options Outstanding Options Exercisable Weighted-Average Weighted Weighted Range of Remaining Average Average Exercise Number of Contractual Life Exercise Number of Exercise Prices Shares (Years) Price Shares Price $0.28 - $0.49 106 1.89 $ 0.36 106 $ 0.36 $2.73 - $4.00 762 6.90 $ 3.61 465 $ 3.39 $4.67 - $7.42 876 8.03 $ 6.55 387 $ 6.81 $8.96 - $15.33 733 8.14 $ 10.33 304 $ 10.80 2,477 7.45 $ 6.50 1,262 $ 5.97
Allocation of Stock Option Compensation Expense	Stock-based compensation is included in the consolidated statements of operations and comprehensive loss in general and administrative, research and development or sales and marketing expenses, depending upon the nature of services provided. Stock-based compensation expense recorded to operations for stock options for both employees and non-employees was as follows: Years Ended December 31, 2016 2015 2014 Sales and marketing $ 677 $ 579 $ 345 Research and development 632 414 180 General and administrative 1,812 738 618 $ 3,121 $ 1,731 $ 1,143
Schedule of Fair Value Calculation Assumptions	The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option pricing model under the following assumptions: Years Ended December 31, 2016 2015 2014 Dividend yield — — — Risk-free interest rate 1.24% - 2.37 % 1.41% - 2.50 % 0.97% - 2.61 % Expected term (in years) 5.27-10 5.52-10 3-10 Volatility 77%-83 % 73%-76 % 66%-75 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of domestic and foreign components of pre-tax loss	The domestic and foreign components of pre-tax loss for the years ended December 31, 2016, 2015, and 2014 were as follows: Years Ended December 31, 2016 2015 2014 Domestic $ (21,458) $ (19,918) $ (33,750) Foreign (2,012) 328 113 Loss before income taxes $ (23,470) $ (19,590) $ (33,637)
Schedule of income tax expense (benefit) differed from the amounts computed by applying the statutory federal income tax rate to pretax income (loss)	Income tax expense (benefit) for the years ended December 31, 2016, 2015, and 2014 differed from the amounts computed by applying the statutory federal income tax rate of 34% to pretax income (loss) as a result of the following: Years Ended December 31, 2016 2015 2014 Federal tax at statutory rate 34.0 % 34.0 % 34.0 % State tax, net of federal tax effect - - 1.5 R&D credit 0.9 0.5 0.3 Change in valuation allowance (40.8) (38.4) (18.9) Non- deductible expenses (0.2) (1.0) (.2) Unrealized (gain) loss on warrant 6.2 4.3 Foreign (0.4) 0.5 (0.1) Other 0.3 0.1 0.1 Total tax expense - % - % - %
Schedule of tax effects of temporary differences and related deferred tax assets and liabilities	The tax effects of temporary differences and related deferred tax assets and liabilities as of December 31, 2016 and 2015 were as follows: December 31, 2016 2015 Deferred tax assets: Depreciation and other $ 61 $ - Net operating loss carryforwards 35,647 26,826 Unused R& D tax credits 872 530 Accruals & reserves 951 317 Deferred Revenue 246 693 Stock Compensation 2,430 1,222 Other 86 43 Deferred tax liabilities: Depreciation and other - (220) Prepaid expenses (168) (113) Less: Valuation allowance (40,125) (29,298) Net deferred tax asset (liability) $ - $ -
Schedule of reconciliation of the beginning and ending amount of unrecognized tax benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits were as follows: Balance at December 31, 2013 $ 93 Increase of unrecognized tax benefits taken in prior years 4 Increase of unrecognized tax benefits related to current year 46 Balance at December 31, 2014 143 Decrease of unrecognized tax benefits taken in prior years (19) Increase of unrecognized tax benefits related to current year 75 Balance at December 31, 2015 199 Increase of unrecognized tax benefits taken in prior years 4 Increase of unrecognized tax benefits related to current year 132 Balance at December 31, 2016 $ 335

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of contractual obligation, fiscal year maturity	The following table summarizes our outstanding contractual obligations, including interest payments, as of December 31, 2016 and the effect those obligations are expected to have on our liquidity and cash flows in future periods: Payments Due By Period Less than Total one year 1-3 Years 4-5 Years After 5 Years Term loan $ 8,345 $ 397 $ 7,508 $ 440 $ - Facility operating lease 2,552 461 1,481 610 - Capital lease 136 40 96 - - Leasehold improvement loan 20 20 - - - Total $ 11,053 $ 918 $ 9,085 $ 1,050 $ -

Segment Disclosures (Tables)

Segment Disclosures (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	Segment reporting information is as follows: Medical Industrial Engineering Devices Sales Services Total Year ended December 31, 2016 Revenue $ 12,081 $ 1,253 $ 887 $ 14,221 Cost of revenue 9,767 948 559 11,274 Gross profit $ 2,314 $ 305 $ 328 $ 2,947 Year ended December 31, 2015 Revenue $ 4,252 $ - $ 4,409 $ 8,661 Cost of revenue 3,926 - 3,556 7,482 Gross profit $ 326 $ - $ 853 $ 1,179 Year ended December 31, 2014 Revenue $ 2,924 $ - $ 2,403 $ 5,327 Cost of revenue 2,048 - 1,720 3,768 Gross profit $ 876 $ - $ 683 $ 1,559
Schedule of Geographic Information	Geographic revenue information based on location of customer is as follows: Years Ended December 31 2016 2015 2014 United States $ 9,042 $ 6,382 $ 3,873 All Other 5,179 2,279 1,454 $ 14,221 $ 8,661 $ 5,327

Quarterly Data (Unaudited) (Tab

Quarterly Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	The following is a summary of quarterly results of operation for the years ended December 31, 2016 and 2015: Quarter Ended March 31 June 30 September 30 December 31 2016 Revenue $ 8,486 $ 1,552 $ 1,596 $ 2,587 Gross profit 1,498 203 403 843 Net loss (3,651) (5,765) (8,478) (5,576) Net loss applicable to common shareholders (6,775) (9,970) (11,494) (5,576) Basic net loss per share (1) (0.44) (0.61) (0.60) (0.29) Diluted net loss per share (1) $ (0.44) $ (0.61) $ (0.60) $ (0.35) 2015 Revenue $ 1,689 $ 2,114 $ 2,915 $ 1,943 Gross profit 403 502 468 (194) Net income (loss) (4,115) (5,645) (5,185) (4,645) Net loss applicable to common shareholders (4,115) (5,645) (5,185) (9,300) Basic and diluted net loss per share (1) $ (0.28) $ (0.39) $ (0.35) $ (0.63) (1) Quarterly net loss per common share amounts may not total to the annual amounts due to rounding and the changes in the number of weighted common shares outstanding and included in the calculation of basic and diluted common shares.

Organization (Details Textual)

Organization (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Jan. 31, 2017	Dec. 31, 2013
Organization [Line Items]
Retained Earnings (Accumulated Deficit), Total	$ (114,861)	$ (91,391)
Cash and Cash Equivalents, at Carrying Value, Total	16,846	19,552	$ 25,190		$ 805
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	(24,997)	$ (18,269)	$ (15,007)
Unrestricted Cash And Cash Equivalents	$ 10,820
Subsequent Event [Member]
Organization [Line Items]
Restricted Cash and Cash Equivalents				$ 6,026

Summary of Significant Accoun42

Summary of Significant Accounting Policies and Estimates (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Balance at December 31, 2015	$ (1)
Other comprehensive loss before reclassification	80
Amounts reclassified from accumulated other comprehensive income (loss)	0
Net current period other comprehensive income	80
Balance at December 31, 2016	$ 79

Summary of Significant Accoun43

Summary of Significant Accounting Policies and Estimates (Details 1) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred Revenue Arrangement [Line Items]
Deferred Rent Credit	$ 60	$ 71
Deferred Revenue	1,630	8,573
Less current portion	(825)	(3,960)
Deferred revenues, non-current	805	4,613
Deferred medical device unit costs	0	4,590
Less current portion	0	2,088
Deferred cost of revenue, non-current	0	2,502
Customer deposits and advances [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue	47	48
Deferred medical device revenues [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue	0	7,388
Deferred extended maintenance and support [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue	$ 1,523	$ 1,066

Summary of Significant Accoun44

Summary of Significant Accounting Policies and Estimates (Details 2) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2016		Sep. 30, 2016		Jun. 30, 2016		Mar. 31, 2016		Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	[1]	Dec. 31, 2015	Dec. 31, 2014
Numerator:
Net loss applicable to common stockholders	$ (5,576)		$ (11,494)		$ (9,970)		$ (6,775)		$ (9,300)	$ (5,185)	$ (5,645)	$ (4,115)	$ (33,815)		$ (24,245)	$ (33,769)
Adjustment for gain on fair value of warrant liability													(4,286)		(2,505)	0
Adjusted net loss used for dilution calculation													$ (38,101)		$ (26,750)	$ (33,769)
Denominator
Weighted-average number of shares outstanding													18,126		14,606	11,181
Effect of potential dilutive shares													496		3	0
Dilutive weighted-average number of shares outstanding													18,622		14,609	11,181
Net loss per share applicable to common stockholders
Basic (in dollars per share)	$ (0.29)	[2]	$ (0.60)	[2]	$ (0.61)	[2]	$ (0.44)	[2]					$ (1.87)		$ (1.66)	$ (3.02)
Diluted (in dollars per share)	$ (0.35)	[2]	$ (0.60)	[2]	$ (0.61)	[2]	$ (0.44)	[2]					$ (2.05)		$ (1.83)	$ (3.02)
[1]	Recognition of previously deferred revenue and cost of goods in the year ended December 31, 2016 reduced net loss applicable to common stockholders by $2,358, or $0.13 per share (see Note 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates – Medical Device Revenue and Cost of Revenue Recognition).
[2]	Quarterly net loss per common share amounts may not total to the annual amounts due to rounding and the changes in the number of weighted common shares outstanding and included in the calculation of basic and diluted common shares.

Summary of Significant Accoun45

Summary of Significant Accounting Policies and Estimates (Details 3) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	4,440	5,802	3,513
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	2,477	1,963	1,542
Warrants for common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,963	1,963	1,971
Common stock issuable upon conversion of preferred shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	0	1,876	0

Summary of Significant Accoun46

Summary of Significant Accounting Policies and Estimates (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Advertising costs	$ 104	$ 25	$ 1
Debt Issuance Cost [Member] | Accounting Standards Update 2015-03 [Member]
Significant Accounting Policies [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets	95
Medical Device [Member]
Significant Accounting Policies [Line Items]
Deferred Revenue, Revenue Recognized		6,517
Cost of Revenue		$ 4,159
Product Liability Accrual, Component Amount	212
Customer Advances and Deposits, Current	911
Reduction In Net Loss Attributable To Common Stock Holders	$ 2,358
Reduction Percentage In Net Loss Attributable To Common Stock Holders	$ 0.13
Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage	10.00%
Customer One [Member] | Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage	18.00%	10.00%	22.00%
Customer One [Member] | Sales Revenue, Net [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		33.00%	12.00%
Customer Two [Member] | Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage	16.00%		11.00%
Customer Three [Member] | Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage	11.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage	10.00%

2014 Merger, Offering and Other

2014 Merger, Offering and Other Related Transactions (Details Textual) $ / shares in Units, $ in Thousands	Jun. 10, 2015shares	Feb. 06, 2014shares	Nov. 30, 2013USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)shares	Dec. 23, 2015shares	Nov. 30, 2014$ / sharesshares	Oct. 31, 2014$ / sharesshares	Mar. 31, 2014shares
Debt Instrument [Line Items]
Equity Issued During Period Units New Issues		1,389,000
Repayments of Notes Payable | $				$ 79	$ 60	$ 2,596
Payments of Stock Issuance Costs | $				173	0	$ 0
Payment of Financing and Stock Issuance Costs, Total | $				$ 1,373	$ 779
Debt Instrument, Convertible, Conversion Price | $ / shares								$ 7
Stock Issued During Period Shares Acquisitions Previously Held						643,000
Stock Issued During Period Shares Acquisitions New Issues						111,000
Equity Interest						6.80%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized										2,058,000
Equity Incentive Plan 2014 [Member]
Debt Instrument [Line Items]
Equity Issued During Period Units New Issues Price Per Unit | $ / shares				$ 7
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				3,714,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	1,656,000
Equity Incentive Plan 2014 [Member] | Conversion Date [Member]
Debt Instrument [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				1,086,000
Equity Incentive Plan 2014 [Member] | Merger Date [Member]
Debt Instrument [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				329,000
Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							2,122,000
Conversion Of Stock Conversion Ratio				1.6290
Series A-2 Preferred Stock [Member]
Debt Instrument [Line Items]
Conversion Of Stock Conversion Ratio				1.9548
Series B Preferred Stock [Member]
Debt Instrument [Line Items]
Conversion Of Stock Conversion Ratio				1.9548
Equity Option [Member]
Debt Instrument [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares						1,086,000
Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Converted						713,000
Common Stock [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 1.75	$ 9.66
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					88,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares						6,088,000
Conversion Of Stock Conversion Ratio				1.5238
Common Stock [Member] | Pre Merger [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Shares, Acquisitions						754
Common Stock [Member] | Equity Incentive Plan 2014 [Member]
Debt Instrument [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				2,058,000
Warrant [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 14					$ 14
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				5,151,000	2,122,000				4,329,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares						89,000
2013 Bridge Loan [Member]
Debt Instrument [Line Items]
Equity Issued During Period Units New Issues				2,940,000
Equity Issued During Period Units New Issues Price Per Unit | $ / shares				$ 7
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				714,000
Proceeds from Convertible Debt | $				$ 25,300
Repayments of Notes Payable | $				2,553
Payments of Stock Issuance Costs | $				3,338
Debt Instrument, Periodic Payment, Principal | $			$ 5,000
Debt Instrument, Periodic Payment, Interest | $			$ 83
Debt Instrument, Periodic Payment, Total | $				$ 5,083
Bridge Notes Placement Agent Warrants [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 7
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				357,000
Class of Warrant or Right Expiration Period				5 years
Bridge warrants [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 7
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			714,000
Class of Warrant or Right Expiration Period			3 years
Debt Conversion, Converted Instrument, Warrants or Options Issued			357,000
Bridge Agent Warrants [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 7
Class of Warrant or Right Expiration Period				5 years
Debt Conversion, Converted Instrument, Warrants or Options Issued				71,000
PPO warrants [Member]
Debt Instrument [Line Items]
Equity Issued During Period Units New Issues				4,329,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 14
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								3,251,000
PPO warrants [Member] | 2013 Bridge Loan [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 14

Equipois Acquisition (Details)

Equipois Acquisition (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Stock consideration (112 shares)	$ 1,071
Estimated contingent consideration	768
Total purchase price	$ 1,839	$ 1,839

Equipois Acquisition (Details 1

Equipois Acquisition (Details 1) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Fixed assets	$ 40
Intangible assets	1,610	$ 1,610
Total identifiable assets acquired	1,650
Goodwill	189	$ 189
Net assets acquired	$ 1,839

Equipois Acquisition (Details 2

Equipois Acquisition (Details 2) - Equipois [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Acquired Indefinite-lived Intangible Assets [Line Items]
Cost	$ 1,610
Accumulated Amortization	(584)
Net	1,026
Developed Technology Rights [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Cost	1,160
Accumulated Amortization	(421)
Net	$ 739
Estimated Useful Life	3 years
Customer Relationships [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Cost	$ 70
Accumulated Amortization	(25)
Net	$ 45
Estimated Useful Life	3 years
Customer Lists [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Cost	$ 380
Accumulated Amortization	(138)
Net	$ 242
Estimated Useful Life	3 years

Equipois Acquisition (Details 3

Equipois Acquisition (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenue	$ 9,434	$ 5,449
Net loss	$ (19,590)	$ (33,978)

Equipois Acquisition (Details T

Equipois Acquisition (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability	$ 768
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low	157
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	521
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High	1,750
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, Low	$ 3,000
Expiration Date of The Buyout Payment Provision	Nov. 30, 2017
Fair Value Inputs, Discount Rate	15.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 1,610	$ 1,610
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	3 years	3 years
Amortization of Intangible Assets	$ 558	$ 26
Goodwill	189	189
Business Combination, Consideration Transferred, Total	1,839	1,839
Change In Fair Value Contingent Consideration	196	0	$ 0
Stock Issued During Period, Value, Acquisitions	$ 500
Business Acquisition, Share Price	$ 7
Business Combination, Contingent Consideration, Liability, Current	$ 355	$ 0
Reseller Agreement [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	125
Other Current Liabilities [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability, Current	$ 355
Equipois, LLC [Member]
Business Acquisition [Line Items]
Business Acquisition, Name of Acquired Entity		Equipois, LLC
Payments to Acquire Businesses, Gross		$ 1,100
Stock Issued During Period, Shares, Acquisitions	112
Business Combination, Contingent Consideration, Liability	$ 500
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low	125
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 375
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Significant Inputs	(a) 7.5 multiplied by 10% of specified product revenues of Equipois during the preceding four complete quarters, plus (b) 7.5 multiplied by 5% of specified product revenues of the Company during the preceding four complete quarters.
Goodwill		$ 189
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 537
Finite-Lived Intangible Assets, Amortization Expense, Year Two	$ 489

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Liabilities:
Warrant liability	$ (3,546)	$ (9,195)
Contingent Success Fee Liability	116
Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	3,546	9,195
Contingent consideration liability	217	768
Contingent Success Fee Liability	116
Quoted Prices in Active Markets for Identical Items Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	0	0
Contingent consideration liability	0	0
Contingent Success Fee Liability	0
Significant Other Observable Inputs Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	0	0
Contingent consideration liability	0	0
Contingent Success Fee Liability	0
Significant Unobservable Inputs Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Liabilities:
Warrant liability	3,546	9,195
Contingent consideration liability	217	$ 768
Contingent Success Fee Liability	$ 116

Fair Value Measurements (Deta54

Fair Value Measurements (Details 1) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Derivative Financial Instruments, Liabilities [Member]
Balance at December 31, 2015	$ 9,195
Reclassification of warrant liability to equity upon exercise of warrants	(1,363)
Gain on decrease in fair value of warrants issued with 2015 financing	(4,286)
Reclassification of contingent consideration liability to accrued liabilities	0
Gain on re-measurement of fair value of contingent consideration liability transferred to accrued liabilities	0
Balance at December 31, 2016	3,546
Contingent Consideration [Member]
Balance at December 31, 2015	768
Reclassification of warrant liability to equity upon exercise of warrants	0
Gain on decrease in fair value of warrants issued with 2015 financing	0
Reclassification of contingent consideration liability to accrued liabilities	(355)
Gain on re-measurement of fair value of contingent consideration liability transferred to accrued liabilities	(196)
Balance at December 31, 2016	217
Contingent Success Fee [Member]
Balance at December 31, 2015	0
Reclassification of warrant liability to equity upon exercise of warrants	0
Gain on decrease in fair value of warrants issued with 2015 financing	0
Reclassification of contingent consideration liability to accrued liabilities	0
Gain on re-measurement of fair value of contingent consideration liability transferred to accrued liabilities	0
Fair value of contingent success fee related to long-term debt	116
Balance at December 31, 2016	$ 116

Fair Value Measurements (Deta55

Fair Value Measurements (Details Textual) - Derivative Financial Instruments, Liabilities [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Beginning Balance	$ 3,546	$ 9,195
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances	$ 4,286

Inventories, net (Details)

Inventories, net (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Raw materials	$ 1,193	$ 783
Work in progress	198	336
Finished goods	267	19
Inventory, Gross	1,658	1,138
Less: inventory reserve	(102)	(82)
Inventories, net	$ 1,556	$ 1,056

Property and Equipment, net (De

Property and Equipment, net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross, Total	$ 5,811	$ 4,878
Accumulated depreciation and amortization	(3,376)	(2,253)
Property and equipment, net	2,435	2,625
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross, Total	$ 3,432	3,097
Machinery and equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated life	3 years
Machinery and equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated life	5 years
Computers and peripherals [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross, Total	$ 564	460
Computers and peripherals [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated life	3 years
Computers and peripherals [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated life	7 years
Computer software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross, Total	$ 547	148
Computer software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated life	3 years
Computer software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated life	7 years
Leasehold improvement [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross, Total	$ 625	625
Leasehold improvement [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated life	5 years
Leasehold improvement [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated life	10 years
Tools, molds, dies and jigs [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross, Total	$ 50	37
Estimated life	5 years
Furniture, office and leased equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross, Total	$ 593	$ 511
Furniture, office and leased equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated life	3 years
Furniture, office and leased equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated life	13 years

Property and Equipment, net (58

Property and Equipment, net (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Depreciation, Depletion and Amortization	$ 1,855	$ 933	$ 745

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accrued Liabilities [Line Items]
Salaries, benefits and related expenses	$ 2,349	$ 1,464
Maintenance	483	0
Warranty expense	203	0
Professional fees	56	257
Equipois earn-out	355	0
Other	110	164
Total	$ 3,556	$ 1,885

Accrued Liabilities (Details 1)

Accrued Liabilities (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016
Accrued Liabilities [Line Items]
Beginning Balance	$ 0	$ 126
Additions for estimated future expense	1,341
Incurred costs	(654)	126
Closing Balance	687	0
Current portion			$ 686
Long-term portion			1
Total	0	0	687
Maintenance [Member]
Accrued Liabilities [Line Items]
Beginning Balance	0	0
Additions for estimated future expense	911
Incurred costs	(428)	0
Closing Balance	483	0
Current portion			483
Long-term portion			0
Total	0	0	483
Warranty [Member]
Accrued Liabilities [Line Items]
Beginning Balance	0	126
Additions for estimated future expense	430
Incurred costs	(226)	(126)
Closing Balance	204	0
Current portion			203
Long-term portion			1
Total	$ 0	$ 0	$ 204

Accrued Liabilities (Details Te

Accrued Liabilities (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Accrued Liabilities [Line Items]
Cost of Property Repairs and Maintenance	$ 911

Long-Term Debt (Details)

Long-Term Debt (Details) $ in Thousands	Dec. 31, 2016USD ($)
2,017	$ 0
2,018	2,139
2,019	2,333
2,020	2,333
2,021	195
Total principal payments	7,000
Less issuance costs & debt discount	211
Long-term debt, net	$ 6,789

Long-Term Debt (Details Textual

Long-Term Debt (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Jan. 31, 2017	Dec. 30, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Success Fee Expenses	$ 250
Share Price	$ 8
Contingent Success Fee Liability	$ 116
Debt Instrument, Interest Rate, Stated Percentage	6.27%
Cash and Cash Equivalents, at Carrying Value, Total	$ 16,846			$ 19,552	$ 25,190	$ 805
Subsequent Event [Member]
Restricted Cash and Cash Equivalents		$ 6,026
Loan Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 10,000
Maximum Cash Proceeds On stock Issuance Required For Loan Disbursement	$ 15,000
Debt Instrument, Description of Variable Rate Basis	30 day U.S. LIBOR rate plus 5.41%.
Debt Instrument, Basis Spread on Variable Rate	5.41%
Principal Percentage Due On Maturity	3.50%
Debt Instrument, Maturity Date	Jan. 1, 2021
Debt Instrument Prepayment Fee Percentage	1.00%
Debt Instrument, Debt Default, Description of Violation or Event of Default	Events of default which may cause repayment of the Term Loans to be accelerated include, among other customary events of default, (1) non-payment of any obligation when due, (2) the Company’s failure to comply with its affirmative and negative covenants, (3) the Company’s failure to perform any other obligation required under the Loan Agreement and to cure such default within a 30 days after becoming aware of such failure, (4) the occurrence of a Material Adverse Effect, (5) the attachment or seizure of a material portion of the Company’s assets if such attachment or seizure is not released, discharged or rescinded within 10 days, (6) bankruptcy or insolvency of the Company, (7) default by the Company under any agreement (i) resulting in a right by a third party to accelerate indebtedness in an amount in excess of $250 or (ii) that would reasonably be expected to have a Material Adverse Effect, (8) entry of a final, uninsured judgment or judgments against the Borrower for the payment of money in an amount, individually or in the aggregate, of at least $250, or (9) any material misrepresentation or material misstatement with respect to any warranty or representation set forth in the Loan Agreement.
Loan Agreement [Member] | Term Loan [Member]
Line of Credit Facility, Maximum Borrowing Capacity			7,000
Loan Agreement [Member] | Term Loan B [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 3,000

Lease and Note Obligations (Det

Lease and Note Obligations (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
2,017	$ 60
2,018	37
2,019	37
2,020	22
2,021	0
Thereafter	0
Total minimum payments	156
Less interest	(12)
Present value minimum payments	144
Less current portion	(54)	$ (80)
Long-term portion	90
Lease hold Improvement Note [Member]
Debt Instrument [Line Items]
2,017	20
2,018	0
2,019	0
2,020	0
2,021	0
Thereafter	0
Total minimum payments	20
Less interest	(1)
Present value minimum payments	19
Less current portion	(19)
Long-term portion	0
Capital Lease Obligations [Member]
Debt Instrument [Line Items]
2,017	40
2,018	37
2,019	37
2,020	22
2,021	0
Thereafter	0
Total minimum payments	136
Less interest	(11)
Present value minimum payments	125
Less current portion	(35)
Long-term portion	90
Operating Lease [Member]
Debt Instrument [Line Items]
2,017	461
2,018	483
2,019	494
2,020	504
2,021	429
Thereafter	181
Total minimum payments	$ 2,552

Lease and Note Obligations (D65

Lease and Note Obligations (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 7,000
Debt Instrument, Interest Rate, Stated Percentage	6.27%
Operating Leases, Rent Expense, Net, Total	$ 400	$ 342	$ 343
Lessee Leasing Arrangements, Operating Leases, Term of Contract	5 years
Lessee Leasing Arrangements, Operating Leases, Renewal Term	5 years
Capital Lease Obligations [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 166
Debt Instrument, Interest Rate, Stated Percentage	4.70%
Debt Instrument, Maturity Date	Jul. 1, 2020
Debt Instrument Minimum Monthly Payments	$ 3
Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 200
Debt Instrument, Interest Rate, Stated Percentage	7.00%
Debt Instrument, Maturity Date	May 31, 2017
Debt Instrument Minimum Monthly Payments	$ 4

Related Party Transactions (Det

Related Party Transactions (Details Textual) - Investor [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Related Party Transaction, Amounts of Transaction	$ 146	$ 50	$ 391
Due to Related Parties, Current	$ 23	$ 10

Capitalization and Equity Str67

Capitalization and Equity Structure (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Schedule of Capitalization, Equity [Line Items]
Merger/PPO Warrant Shares Outstanding	3,597	4,085
Merger/PPO Warrant Shares Exercised	488
Placement agent warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 7
Warrant term	5 years
Merger/PPO Warrant Shares Outstanding	426	426
Merger/PPO Warrant Shares Exercised	0
Bridge warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 7
Warrant term	3 years
Merger/PPO Warrant Shares Outstanding	371	371
Merger/PPO Warrant Shares Exercised	0
PPO warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 14
Warrant term	5 years
Merger/PPO Warrant Shares Outstanding	1,078	1,078
Merger/PPO Warrant Shares Exercised	0
Pre 2014 Warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 9.66
Merger/PPO Warrant Shares Outstanding	88	88
Merger/PPO Warrant Shares Exercised	0
2015 Warrants [Member]
Schedule of Capitalization, Equity [Line Items]
Exercise price	$ 3.74
Warrant term	5 years
Merger/PPO Warrant Shares Outstanding	1,634	2,122
Merger/PPO Warrant Shares Exercised	488

Capitalization and Equity Str68

Capitalization and Equity Structure (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Schedule of Capitalization, Equity [Line Items]
Current Share Price	$ 8
Warrant [Member]
Schedule of Capitalization, Equity [Line Items]
Current Share Price	1.51
Black-Scholes Option Pricing Model [Member] | Warrant [Member]
Schedule of Capitalization, Equity [Line Items]
Current Share Price	3.98	$ 7.14
Conversion Price	$ 3.74	$ 8.25
Risk-free interest rate	1.70%	1.76%
Periodic rate		0.88%
Time to Maturity (years)	3 years 11 months 23 days	4 years 11 months 23 days
Volatility of stock	70.00%	75.00%

Capitalization and Equity Str69

Capitalization and Equity Structure (Details 2)	12 Months Ended
	Dec. 31, 2016$ / shares
Schedule of Capitalization, Equity [Line Items]
Share price at final valuation	$ 8
Warrant [Member]
Schedule of Capitalization, Equity [Line Items]
Dividend yield	0.00%
Share price at final valuation	$ 1.51
Warrant [Member] | Minimum [Member]
Schedule of Capitalization, Equity [Line Items]
Risk-free interest rate	0.60%
Expected term (in years)	2 years 1 month 24 days
Volatility	65.00%
Warrant [Member] | Maximum [Member]
Schedule of Capitalization, Equity [Line Items]
Risk-free interest rate	1.73%
Expected term (in years)	4 years 9 months 18 days
Volatility	79.00%

Capitalization and Equity Str70

Capitalization and Equity Structure (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Aug. 12, 2016	Aug. 31, 2016	Dec. 23, 2015	Nov. 30, 2014	Oct. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Common Stock, Shares Authorized						71,429,000	71,429,000
Preferred Stock, Shares Authorized						10,000,000	10,000,000
Common Stock, Shares, Issued						21,894,000	15,027,000
Preferred Stock, Shares Issued						0	13,000
Preferred Stock, Shares Outstanding			3,000			0	13,000
Stock Issued During Period, Shares, New Issues					89,000
Gross Proceeds from Preferred Stock and Warrants			$ 15,000
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants, Total			13,906			$ 0	$ 13,906	$ 0
Stock Related Expenses Payable			$ 173
Preferred Stock Converted Into Common stock			3,300,000
Fair Value Adjustment of Warrants						135	0	0
Proceeds from Warrant Exercises						1,825	53	21,412
Amortization of Financing Costs and Discounts, Total							1,355
Warrants Not Settleable in Cash, Fair Value Disclosure						$ 11,700
Conversion of Stock, Shares Issued		267				1,389,000
Proceeds from Issuance of Common Stock						$ 14,694	$ 0	21,961
Preferred Stock Convertible Conversion Price						$ 7.07	$ 7.07
Conversion of Stock, Shares Converted		921,000
Stockholders' Equity, Reverse Stock Split						1-for-7 reverse
Minimum [Member]
Class of Stock [Line Items]
Preferred Stock Convertible Conversion Price						$ 3.74
Maximum [Member]
Class of Stock [Line Items]
Preferred Stock Convertible Conversion Price						$ 7.07
2016 Equity Offering [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Issued	267,000						141
Over-Allotment Option [Member]
Class of Stock [Line Items]
Proceeds from Issuance of Common Stock	$ 998
Offer to Amend and Exercise [Member]
Class of Stock [Line Items]
Fair Value Adjustment of Warrants								$ 16,485
Proceeds from Warrant Exercises					$ 22,756
Warrant Solicitation Costs					$ 1,467
Transfer of warrant liability to equity				$ 27,099
Warrant [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Issued			15,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					4,329,000	5,151,000	2,122,000
Preferred Shares and Warrants Purchase Price						$ 487
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 14	$ 14
Maximum Financing in Anti Dilution Provision						$ 10,000
Warrants Term							5 years
Warrant [Member] | Minimum [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 3.74
Warrant [Member] | Maximum [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 8.75
Warrant [Member] | Offer to Amend and Exercise [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 7	$ 7
Warrant [Member] | Merger and PPO [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						4,329,000
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues						4,017,000	0
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							88,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1.75	$ 9.66
Common Stock [Member] | 2016 Equity Offering [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	3,750,000
Sale of Stock, Price Per Share	$ 4
Proceeds from Issuance of Common Stock	$ 13,696
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			2,122,000
Conversion of Stock, Shares Issued						921,000
Preferred Stock Convertible Conversion Price						$ 3.74
Conversion of Stock, Shares Converted						3,000
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Outstanding							13,000
Amortization of Financing Costs and Discounts, Total						$ 10,345
Conversion of Stock, Shares Converted						10,000	2,000

Employee Stock Options (Details

Employee Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares
Options Outstanding
Aggregate Intrinsic Value, Exercisable | $	$ 103
2014 Plan [Member]
Options Outstanding
Options Outstanding, Beginning Balance | shares	1,963
Options Outstanding, Options granted | shares	813
Options Outstanding, Options exercised | shares	(44)
Options Outstanding, Options forfeited | shares	(224)
Options Outstanding, Options cancelled | shares	(31)
Options Outstanding, Ending Balance | shares	2,477
Options Outstanding, Vested and expected to vest | shares	2,321
Options Outstanding, Exercisable | shares	1,262
Weighted-Average Exercise Price, Beginning Balance | $ / shares	$ 7.09
Weighted-Average Exercise Price, Options granted | $ / shares	5.40
Weighted-Average Exercise Price, Options exercised | $ / shares	2.51
Weighted-Average Exercise Price, Options forfeited | $ / shares	8.06
Weighted-Average Exercise Price, Options cancelled | $ / shares	9.39
Weighted-Average Exercise Price, Ending Balance | $ / shares	6.50
Weighted-Average Exercise Price, Vested and expected to vest | $ / shares	6.49
Weighted-Average Exercise Price, Exercisable | $ / shares	$ 5.97
Weighted-Average Remaining Contractual Life (Years), Ending Balance	7 years 5 months 16 days
Weighted-Average Remaining Contractual Life (Years), Vested and expected to vest	7 years 4 months 2 days
Weighted-Average Remaining Contractual Life (Years), Exercisable	6 years 4 days
Aggregate Intrinsic Value, Ending Balance | $	$ 674
Aggregate Intrinsic Value, Vested and expected to vest | $	672
Aggregate Intrinsic Value, Exercisable | $	$ 659

Employee Stock Options (Detai72

Employee Stock Options (Details 1) shares in Thousands	12 Months Ended
	Dec. 31, 2016shares
Shares Available For Grant	1,506
Shares Available For Grant, Granted	(813)
Shares Available For Grant, Forfeited	224
Shares Available For Grant, Expired	31
Shares Available For Grant	948

Employee Stock Options (Detai73

Employee Stock Options (Details 2) shares in Thousands	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options, Beginning Balance | shares	2,477
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	7 years 5 months 12 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price	$ 6.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options, Beginning Balance | shares	1,262
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	$ 5.97
Exercise Price Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	0.28
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 0.49
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options, Beginning Balance | shares	106
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	1 year 10 months 20 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price	$ 0.36
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options, Beginning Balance | shares	106
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	$ 0.36
Exercise Price Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	2.73
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 4
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options, Beginning Balance | shares	762
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	6 years 10 months 24 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price	$ 3.61
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options, Beginning Balance | shares	465
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	$ 3.39
Exercise Price Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	4.67
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 7.42
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options, Beginning Balance | shares	876
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	8 years 11 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price	$ 6.55
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options, Beginning Balance | shares	387
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	$ 6.81
Exercise Price Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	8.96
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 15.33
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options, Beginning Balance | shares	733
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	8 years 1 month 20 days
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price	$ 10.33
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options, Beginning Balance | shares	304
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price	$ 10.80

Employee Stock Options (Detai74

Employee Stock Options (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 3,121	$ 1,731	$ 1,143
Sales and marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	677	579	345
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	632	414	180
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 1,812	$ 738	$ 618

Employee Stock Options (Detai75

Employee Stock Options (Details 4)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%
Risk-free interest rate, minimum	1.24%	1.41%	0.97%
Risk-free interest rate, maximum	2.37%	2.50%	2.61%
Volatility, minimum	77.00%	73.00%	66.00%
Volatility, maximum	83.00%	76.00%	75.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years 3 months 7 days	5 years 6 months 7 days	3 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	10 years	10 years	10 years

Employee Stock Options (Detai76

Employee Stock Options (Details Textual) $ / shares in Units, shares in Thousands, $ in Thousands	Jun. 10, 2015shares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)$ / sharesshares	Mar. 31, 2014shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares					2,058
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares		948	1,506
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		$ 103
Proceeds from Stock Options Exercised		110	$ 225	$ 102
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost				411
Share-based Compensation, Total		3,121	$ 1,731	$ 1,143
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total		59
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total		774
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 4,822
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 2,456
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares				122
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Number of Employees Affected				14
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit | $ / shares				$ 24.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit | $ / shares				45.50
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares				$ 15.33
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares		$ 3.52
Equity Incentive Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares		3,714
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Conversion Of Prior Plan | shares		1,086
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | shares	1,656
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares		948
Equity Incentive Plan 2014 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		4 years
Equity Incentive Plan 2014 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest [Abstract]
Domestic	$ (21,458)	$ (19,918)	$ (33,750)
Foreign	(2,012)	328	113
Loss before income taxes	$ (23,470)	$ (19,590)	$ (33,637)

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Federal tax at statutory rate	34.00%	34.00%	34.00%
State tax, net of federal tax effect	0.00%	0.00%	1.50%
R&D credit	0.90%	0.50%	0.30%
Change in valuation allowance	(40.80%)	(38.40%)	(18.90%)
Non- deductible expenses	(0.20%)	(1.00%)	(0.20%)
Unrealized (gain) loss on warrant	6.20%	4.30%
Foreign	(0.40%)	0.50%	(0.10%)
Other	0.30%	0.10%	0.10%
Total tax expense	0.00%	0.00%	0.00%

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Depreciation and other	$ 61	$ 0
Net operating loss carryforwards	35,647	26,826
Unused R& D tax credits	872	530
Accruals & reserves	951	317
Deferred Revenue	246	693
Stock Compensation	2,430	1,222
Other	86	43
Deferred tax liabilities:
Depreciation and other	0	(220)
Prepaid expenses	(168)	(113)
Less: Valuation allowance	(40,125)	(29,298)
Net deferred tax asset (liability)	$ 0	$ 0

Income Taxes (Details 3)

Income Taxes (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Balance	$ 199	$ 143	$ 93
Increase (decrease) of unrecognized tax benefits taken in prior years	4	(19)	4
Increase (decrease) of unrecognized tax benefits related to current year	132	75	46
Balance	$ 335	$ 199	$ 143

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 10,827	$ 7,983
Federal
Operating Loss Carryforwards	$ 93,749
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2027
Federal | Employee Stock Option [Member]
Deferred Tax Assets, Net of Valuation Allowance, Total	$ 1,684
Federal | Research Tax Credit Carryforward [Member]
Operating Loss Carryforwards	818
State
Operating Loss Carryforwards	$ 76,263
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2017
State | Employee Stock Option [Member]
Deferred Tax Assets, Net of Valuation Allowance, Total	$ 657
Open Tax Year	2,007
State | Research Tax Credit Carryforward [Member]
Operating Loss Carryforwards	$ 524
Foreign Tax Authority [Member]
Operating Loss Carryforwards	$ 2,012

Commitments and Contingencies82

Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2016USD ($)
Payments Due By Period, Less than one year	$ 918
Payments Due By Period, 1 -3 Years	9,085
Payments Due By Period, 4-5 Years	1,050
Payments Due By Period, After 5 Years	0
Payments Due By Period, Total	11,053
Facility operating lease [Member]
Payments Due By Period, Less than one year	461
Payments Due By Period, 1 -3 Years	1,481
Payments Due By Period, 4-5 Years	610
Payments Due By Period, After 5 Years	0
Payments Due By Period, Total	2,552
Leasehold improvement loan [Member]
Payments Due By Period, Less than one year	20
Payments Due By Period, 1 -3 Years	0
Payments Due By Period, 4-5 Years	0
Payments Due By Period, After 5 Years	0
Payments Due By Period, Total	20
Capital lease [Member]
Payments Due By Period, Less than one year	40
Payments Due By Period, 1 -3 Years	96
Payments Due By Period, 4-5 Years	0
Payments Due By Period, After 5 Years	0
Payments Due By Period, Total	136
Term Loan [Member]
Payments Due By Period, Less than one year	397
Payments Due By Period, 1 -3 Years	7,508
Payments Due By Period, 4-5 Years	440
Payments Due By Period, After 5 Years	0
Payments Due By Period, Total	$ 8,345

Commitments and Contingencies83

Commitments and Contingencies (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Future minimum annual royalties:
Payments Due By Period, Less than one year	$ 918
Royalty Agreement Terms [Member]
Future minimum annual royalties:
Payments Due By Period, Less than one year	$ 50
Royalty Agreement Terms [Member] | Net sales [Member]
Future minimum annual royalties:
Royalty Percentage	1.00%
Royalty Agreement Terms [Member] | License fees [Member]
Future minimum annual royalties:
Royalty Percentage	21.00%
Royalty Agreement Terms [Member] | Sub-licensee net sales [Member]
Future minimum annual royalties:
Royalty Percentage	1.00%

Segment Disclosures (Details)

Segment Disclosures (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Revenue	$ 2,587	$ 1,596	$ 1,552	$ 8,486	$ 1,943	$ 2,915	$ 2,114	$ 1,689	$ 14,221	$ 8,661	$ 5,327
Cost of revenue									11,274	7,482	3,768
Gross profit	$ 843	$ 403	$ 203	$ 1,498	$ (194)	$ 468	$ 502	$ 403	2,947	1,179	1,559
Engineering Services [Member]
Segment Reporting Information [Line Items]
Revenue									887	4,409	2,403
Cost of revenue									559	3,556	1,720
Gross profit									328	853	683
Medical Devices [Member]
Segment Reporting Information [Line Items]
Revenue									12,081	4,252	2,924
Cost of revenue									9,767	3,926	2,048
Gross profit									2,314	326	876
Industrial Sales [Member]
Segment Reporting Information [Line Items]
Revenue									1,253	0	0
Cost of revenue									948	0	0
Gross profit									$ 305	$ 0	$ 0

Segment Disclosures (Details 1)

Segment Disclosures (Details 1) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Revenue	$ 2,587	$ 1,596	$ 1,552	$ 8,486	$ 1,943	$ 2,915	$ 2,114	$ 1,689	$ 14,221	$ 8,661	$ 5,327
United States [Member]
Segment Reporting Information [Line Items]
Revenue									9,042	6,382	3,873
All Other [Member]
Segment Reporting Information [Line Items]
Revenue									$ 5,179	$ 2,279	$ 1,454

Quarterly Data (Unaudited) (Det

Quarterly Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended												11 Months Ended	12 Months Ended
		Dec. 31, 2016		Sep. 30, 2016		Jun. 30, 2016		Mar. 31, 2016		Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2016		Dec. 31, 2015	Dec. 31, 2014
Revenue		$ 2,587		$ 1,596		$ 1,552		$ 8,486		$ 1,943	$ 2,915	$ 2,114	$ 1,689		$ 14,221		$ 8,661	$ 5,327
Gross profit		843		403		203		1,498		(194)	468	502	403		2,947		1,179	1,559
Net income (loss)		(5,576)		(8,478)		(5,765)		(3,651)		(4,645)	(5,185)	(5,645)	(4,115)	$ (33,769)	(23,470)		(19,590)	(33,769)
Net loss attributable to common shareholders		$ (5,576)		$ (11,494)		$ (9,970)		$ (6,775)		$ (9,300)	$ (5,185)	$ (5,645)	$ (4,115)		$ (33,815)	[1]	$ (24,245)	$ (33,769)
Basic net loss per share (In dollars per share)		$ (0.29)	[2]	$ (0.60)	[2]	$ (0.61)	[2]	$ (0.44)	[2]						$ (1.87)	[1]	$ (1.66)	$ (3.02)
Diluted net loss per share (In dollars per share)		$ (0.35)	[2]	$ (0.60)	[2]	$ (0.61)	[2]	$ (0.44)	[2]						$ (2.05)	[1]	$ (1.83)	$ (3.02)
Basic and diluted net loss per share (In dollars per share)	[2]									$ (0.63)	$ (0.35)	$ (0.39)	$ (0.28)
[1]	Recognition of previously deferred revenue and cost of goods in the year ended December 31, 2016 reduced net loss applicable to common stockholders by $2,358, or $0.13 per share (see Note 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates – Medical Device Revenue and Cost of Revenue Recognition).
[2]	Quarterly net loss per common share amounts may not total to the annual amounts due to rounding and the changes in the number of weighted common shares outstanding and included in the calculation of basic and diluted common shares.